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ABSTRACT 
Malignant Pleural Mesothelioma (MPM) is an aggressive cancer refractory to current 
therapies, the incidence of which is expected to rise in the next decades. Exposure to 
asbestos is a well-known MPM risk factor. To date, diagnosis is hard to determine, due to a 
lack of proper markers to specifically identify malignant pleural mesothelioma, since it 
might be confused with lung-originated metastatic neoplasm. 
MiRNAs are single stranded noncoding RNAs of 20-22 nucleotides that post-
transcriptionally regulate gene expression by triggering mRNA cleavage or repressing 
translation. One single miRNA can regulate hundreds of mRNAs and a single mRNA can 
be targeted by several different miRNAs. Changes in the expression of miRNAs have been 
implicated in several diseases, including MPM. miRNAs are stable molecules that can be 
easily investigated in different specimens (e.g. blood), and used as a disease biomarker. 
Exhaled breath condensate (EBC) collection is a standardized, non-invasive technique 
and collected EBC is representative of lung environment. miRNAs measured in 
EBC/blood could help evaluating asbestos exposed subjects and MPM development.  
 
Specific aims of the project are: 
Aim 1: Determine whether a specific miRNA signature (in plasma or EBC) may help to 
discriminate between malignant pleural mesothelioma patients and patients affected by 
other pulmonary diseases, among patients presenting at the Thoracic Surgery Unit with a 
diagnosis of pleural effusion.  
Aim 2: Determine whether a specific miRNA signature (in plasma or EBC) may help to 
discriminate between Malignant Pleural Mesothelioma (MPM) patients and healthy 
subjects with a Past Exposure to Asbestos (PEA).  
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Aim 3: Evaluate a possible correlation between miRNAs in EBC and plasma.  
Aim 4: Estimate sensitivity and specificity of altered miRNAs using ROC curves. 
 
To address this hypothesis we investigated a population including 23 MPM patients, 19 
healthy subjects with a Past Asbestos Exposure (PEA), and 9 subjects with pleural 
effusions and affected by other diseases. In this study population we screened 733 
miRNAs in blood and EBC by high-throughput Open Array. To investigate the possible 
miRNAs expression deregulation between the cases and controls, we used a multiple linear 
regression model adjusted for four principal variables (age, sex, BMI and smoking habits) 
and identified 6 candidate miRNAs in EBC and 13 in plasma. 
After Real Time validation, we identified one miRNA in EBC (hsa-miR-30a-5p) and 
three miRNAs in plasma (hsa-miR-151-5p, hsa-miR-107, and hsa-let-7e-5p), able to 
discriminate between MPM and PEA subjects. The combination of the 4 miRNAs gives 
even a better score, with a ROC curve which shows an AUC = 0.85.  
 
To our knowledge, this is the first study in MPM which investigate miRNA expression 
in EBC and identify a 4-miRNA signature which might be useful for MPM diagnosis. This 
signature might help identifying subjects with an increased risk of developing MPM after 
exposure to asbestos.  
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1. BACKGROUND 
1.1. MALIGNANT MESOTHELIOMA EPIDEMIOLOGY – 
THE SIZE OF THE PROBLEM  
Mesothelioma is a rare tumor originating from the mesothelium. The most common site 
is the pleura, but it can also arise in the peritoneum, pericardium, and the tunica vaginalis 
of the testis. 
Malignant pleural mesothelioma is an aggressive cancer refractory to current therapies, 
the incidence of which is expected to rise in the next decades [1]. Recent projections have 
suggested that malignant pleural mesothelioma mortality rates, estimated using mortality 
from primary pleural tumors, will continue to increase in the next 20 years in most 
European countries [2, 3].  
In Italy permanent malignant pleural mesothelioma epidemiologic surveillance has been 
in place since 1993 (mandatory since 2000) by means of a National Mesothelioma Register 
(ReNaM), kept at the Italian Workers’ Compensation Authority (INAIL), and collected 
more than 15000 incident cases. The incidence rates of malignant pleural mesothelioma in 
Italy in the last years are 3.55 and 1.35 per 100,000 in men and women respectively [4]. 
The ReNaM has a regional structure with Operating Centres (COR) operating in almost all 
Italian regions, so covering almost the whole Italian territory. In Lombardy region the 
COR was established in 2000 at the Department of Preventive Medicine Fondazione 
IRCCS Ca’ Granda. It includes all incident cases of mesothelioma of the pleura, 
peritoneum, pericardium, and tunica vaginalis of testis that have been diagnosed among 
subjects living in the region (total population about 10 million). In Lombardy region, the 
standardized (Standard: Italian population 2001) incidence rates of malignant pleural 
mesothelioma (2000-2011) were 4.7 and 1.9 per 100,000 respectively in men and women. 
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1.2. MESOTHELIOMA AND ASBESTOS EXPOSURE 
Asbestos is a trade name encompassing various fibrous silicates that can be classified in 
two main groups: amphiboles and serpentine (Table 1). The International Agency for 
Research on Cancer (IARC) classified all asbestos types as human carcinogens. A general 
consensus exists that amphiboles are more potent in causing MPM than chrysotile although 
the extent of the difference is still debated [5]. 
According to the Second Italian Consensus Conference on pleural mesothelioma [6], 
exposure to asbestos may be classified as: 
a) occupational exposure in asbestos mining or first processing of asbestos; 
b) occupational exposure in trades using asbestos containing materials; 
c) occupational exposure due to jobs in workplaces where asbestos materials are 
present (e.g. insulation); 
d) domestic exposure as family members of asbestos workers; 
e) environmental exposure consequent to dwelling in proximity of asbestos mining, 
industries or deposits of asbestos tailings; 
f) environmental exposure to natural occurring asbestos (NOA). 
 Asbestos was widely used in the construction and shipbuilding industries, especially in 
thermal and acoustic insulation, thanks to its unusual characteristics of plasticity and 
resistance, and also for water- and fire-proofing. Up to the end of the 1980’s, Italy was the 
second largest asbestos producer in Europe, after the Soviet Union, and the largest in the 
European Community. From the end of the Second World War to the asbestos ban in 1992, 
3,748,550 tons of raw asbestos were produced, reaching its peak in the period between 
1976 and 1980 at about 160,000 tons/year [7]. Because of its previous high consumption, 
the wide spectrum of industries involved and the number of workers and non-workers 
exposed, Italy is among countries which are most sensitive to the ‘asbestos’ 
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question and it has a specific system of epidemiological surveillance of mesothelioma. 
The association between asbestos exposure and malignant pleural mesothelioma is well 
established. The background incidence of malignant pleural mesothelioma (without 
asbestos exposure) is estimated to be about 1–2 cases per million per year [8]. Among 
asbestos-exposed populations, the observed number of cases is much higher than expected. 
In the industrialized world, about 80% of malignant pleural mesothelioma develop in 
individuals with higher than background levels of exposure to asbestos [9, 10]. Workers 
involved in the extraction and manufacturing of asbestos fibers – i.e. miners, asbestos-
cement workers, shipyards workers, insulators – have the highest risk of malignant pleural 
mesothelioma [8-11]. Recently, mesothelioma cases and deaths have been found in other 
workplaces, where asbestos exposure was at a low level [12, 13]. The mean latency time 
Table 1 Asbestos classification by International Agency for Research on Cancer 
(IARC). 
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for malignant pleural mesothelioma has been repeatedly found to be between 30 and more 
than 40 years [4, 9]. As a consequence of the strong cause–effect relationship, the 
incidence and mortality trends observed recently follow the asbestos exposure trends with 
a mean lag time of about 30–50 years.  
In Figure 1 is reported the expected number of malignant pleural mesothelioma deaths 
in Italy along with data on asbestos consumption [7]. 
The number of mesothelioma cases reported began to increase around 1950 in some 
countries, with a steep increase noted during 1960s and 1970s. Although preventive 
measures have been taken at different time points in Europe, European cancer registries 
have described constant increases in the incidence rates of malignant pleural mesothelioma 
in the last few decades [14, 15]. 
 
 
 
Figure 1 Italian raw asbestos per-capita consumption (5-year moving average; tons 
per 1,000,000 inhabitants), observed (1970 –1999) and predicted (2000 – 2029) malignant 
pleural mesothelioma deaths among men aged 25–89 years old in Italy. Pleural 
mesothelioma deaths = pleural cancer deaths X 0.73  
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In addition to asbestos group of minerals, there are some other mineral groups that show 
to have a structure resembling characteristics of asbestos. This minerals are classified as 
asbestiform minerals, since they are formed by fibres with long, thin shapes juxtaposed 
between themselves, and easily separable one from another [16]. These types of fibres had 
no or limited industrial use and they include: erionite, fluoro-edenite and vermiculite. 
Erionite is a fibrous zeolite contained in the zeolite stones used to build houses in the 
Cappadocia region of Turkey, where high mesothelioma incidence and mortality were 
observed [17]. Erionite has been recently reported as possible cause of MPM also in other 
countries such as North Dakota [18].  
An high mortality due to malignant pleural tumor has been observed in Italy in the 
Sicilian town of Biancavilla in the years 1980-1993. Ad hoc epidemiological studies and 
environmental monitoring revealed an etiological role of an asbestos-like mineral named 
fluoro-edenite. Fluoro-edenitic fibers were found in the materials extracted from a stone 
quarry located near the city and used in the local building industry, as well as in soils for 
road paving [19].  
Another example of Natural Occurring Asbestos is depicted by exposure to vermiculite, 
a phyllosilicate that expands greatly and exfoliates when heated, in mine workers and 
inhabitants of Libby, Montana (USA). Here, as in the other places, an high mortality for 
malignant pleural mesothelioma has been reported [20]. In addition to occupational 
exposure for miners, vermiculite was extensively used in gardens, driveways, high school 
track and in the insulation of walls of home by the people living in Libby, thus causing 
environmental exposure. Local vermiculite was contaminated by other kind of fibrous 
minerals, classified as asbestiform tremolite-actinolite, along with richerite and winchite 
[21]. 
 11 
 
1.3. DIAGNOSIS 
Most of the patients show to have a fluid accumulation in the pleura by standard 
radiography and physical examinations. Only between the 10 and 20% of patients present 
little or no fluid, which in any case tends to diminish as the disease goes on [22]. Usually, 
pathological confirmation of malignant pleural mesothelioma is represented by imaging 
tests (e.g. radiography, CT scan, MRI and PET scan), cytology test on pleural fluid, 
histology and immunohistochemistry staining on biopsy tissue, and thoracoscopy, usually 
video-assisted. 
1.3.1. DIAGNOSTIC IMAGING 
First line for the diagnosis of malignant pleural mesothelioma is radiography of the 
thorax. Generally, thorax radiography could highlight presence of pleural effusions and 
masses coupled to them. Plaques in the pleura are commonly taken as signs of asbestos 
exposure, but not as presence of malignant pleural mesothelioma. A limit of standard 
radiography is the capacity to discriminate the fluid nature from effusion due to hearth 
failure or other non-malignant diseases. Because pulmonary findings can be obscured by 
pleural disease on chest radiography, computed tomography (CT) would better evaluate for 
pulmonary fibrosis and metastases. 
CT, being a non-invasive procedure, is preferentially chosen in particular in pre-surgery 
organization in that subjects who undergoes to surgery. As radiography, CT can identify 
pleural plaques linked to asbestos exposure. In addition, CT scan can better describe 
aspects of the lesions defining extension and staging of the disease, since it can help to 
identify the fluid and to discern the pleural-based masses, lymph nodes, blood vessels, and 
lung parenchyma from the fluid itself. 
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Another well used diagnosis imaging is represented by magnetic resonance (MRI). 
Enabling the differentiation between tumor mass and normal adjacent tissue, MRI is useful 
in identifying extension of the disease and invasions towards structures close to pleura. In 
addition, thanks to its characteristics, MRI can be useful in planning radiotherapy for 
localized disease. 
Positron-emission tomography (PET) can be helpful in identifying benignant and 
malignant effusions, in addition this imaging test can find metastases that are hidden to the 
other tests. It also appears to be useful for detecting extra thoracic disease, particularly 
lymph-node involvement, and hence has a role in the staging of tumors. Different patterns 
of marker uptake are seen, some of which provide additional information about the extent 
of the disease that is not obvious on CT scans. High standardized uptake values correlate 
with a worse prognosis and also help to differentiate tumor from fibrosis and necrosis in 
some patients. It has been suggested that the results of PET combined with CT scanning 
more accurately reflect the likely response to chemotherapy than do the results of either 
PET or CT scanning alone.
 
Anyway, due to similar clinical and radiological features of primitive pleural or 
peritoneal mesothelioma and secondary metastatic localizations, these tests are not 
sufficient to give a certainty of diagnosis for malignant pleural mesothelioma. Then, it is 
recommended to perform cytological analysis and biopsies to enhance confidence index of 
diagnosis. 
 
1.3.2. BIOPSY PROCEDURE 
Biopsy procedures used in diagnosis are thoracentesis (blind percutaneous needle and 
fine needle aspiration), imaging-guided core biopsy, video-assisted thoracoscopy (VATS) 
and thoracotomy. The method of choice at present to improve diagnosis accuracy is VATS. 
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VATS allows to acquire direct pleural biopsy and drainage of effusions, in order to obtain 
biological material to perform following cytological and histological analysis. In addition, 
VATS allows to visualize whole hemithorax and to perform, in some cases, complete 
pleurodesis preventing reaccumulation of the effusion. By sight with VATS, malignant 
pleural mesothelioma appears to be a firm and greyish tumor that could covers entirely the 
lung with a thick ring of tumor. In addition, the tumor mass can merge to both visceral and 
parietal pleural surfaces forming discrete plaques and nodules. Thus, VATS allows to 
perform accurate visual biopsy and to gain pleural fluid from effusions for cytological 
exams, and specific tumor specimens for histological assays. 
1.3.3. CYTOLOGICAL EXAMINATIONS  
Cytological examinations, as mentioned before, are performed on pleural effusion fluid 
and give some suggestive diagnostic information on the nature of the disease. Alone by 
itself cytological exams can recognize malignant pleural mesothelioma in less than 85%. 
Usually cytological exams are performed in consecutive steps. Starting from identifying 
whether the cells into the fluid are mesothelial, markers, such as calretinin, cytokeratin 5/6, 
and Wilms’ tumor 1 antigen (WT1), are used. The second step is to determine malignancy 
of cells using markers for epithelial membrane antigen (EMA, also known as CA15-3 and 
mucin-1), like E29 or MC-5 antibodies, with E29 characterized by an higher specificity 
than MC-25. Since cytological evidence are not sufficient to determine with certainty the 
nature of the disease, it is often matched with more accurate histological examination.  
1.3.4. HISTOLOGICAL EXAMINATION 
Malignant pleural mesothelioma shows to have an extraordinary morphological variety, 
presenting epithelial peculiarity, with different growth patterns, or sarcomatoid 
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characteristic; in addition it can shows to have a mix of the two previous characteristics. 
Accordingly to its morphology malignant pleural mesothelioma can be classified into three 
main categories: epithelial, sarcomatoid and biphasic. Because of its histological variety, it 
is extremely problematic to discern malignant pleural mesothelioma form neoplasm and 
metastasis originated from other cancers. Metastasis from other tumors infiltrated in the 
serous can show histological morphology often indiscernible from that of the malignant 
pleural mesothelioma. In addition, secondary metastasis can determine reactive 
proliferation of mesothelial cells. Thus, bewilderment can be generated during histological 
diagnosis. 
Diagnosis procedure is based on a multidisciplinary approach with different medical 
experts, i.e. clinician, radiologist, and pathologist. Focusing on the last aspect, pathologists 
base their anatomical pathology diagnosis on macro and micro criteria backed by 
histochemetsry and immunohistochemistry to reach a certainty of diagnosis. 
Immunohistochemistry, based on antigen-antibody reactions, allows to define 
immunophenotype of the tumor through the use of mono or polyclonal antibodies which 
binds in specific manner to given antigens. The most used and principal antigens are listed 
below categorized for being positive or negative markers of mesothelioma (Table 2):  
1. positive markers:  
1.1. keratins and vimentin, when used separately, give limited information for 
differential diagnosis, because they could be expressed both in primary pleural 
tumour and metastatic adenocarcinoma. Keratin 5/6 are reported to be expressed in 
between the 60% and 100% of epithelioid mesotheliomas, depending on the 
dimension of the biopsy specimen, since staining could be restricted to a focal site, 
or even in individual cells while adenocarcinomas and serous carcinomas show to 
have 19% and about 27%, respectively [23-28]. Hence, keratins are quite useful to 
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discriminate mesotheliomas from adenocarcinoma, while these markers are not 
enough specific to discriminate between mesothelioma and serous carcinomas. To 
strengthen diagnosis, vimentin is usually coupled to keratins, since a perinuclear 
staining of both of the two intermediate filaments is suggestive of mesothelioma 
[29]; 
1.2. epithelial membrane antigen (EMA) human milk fat globulin 2 (HMFG-2) are 
related members of a family of high-molecular-weight trans-membranous 
glycoproteins. Both these two glycoproteins stain positive in mesothelioma and 
adenocarcinoma of the lung, but with two different patterns of distribution as are 
respectively expressed on the membrane and in the cytoplasm [30] ; 
1.3. Calretinin is one of the preferred immunomarkers as it is reported to be highly 
specific and sensitive in recognizing malignant pleural mesothelioma. In fact, 
differently from other highly reactive marker that stain specifically epithelioid 
Table 2 Immunohistochemical tests for differential diagnosis of malignant pleural 
mesothelioma. 
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mesothelioma, calretinin shows to be frequently expressed in all mesothelioma 
subtypes. Even if there are some conflicting about percentage of positive staining 
in adenocarcinomas and other types of carcinoma, usually calretinin is reported to 
have a strong, diffuse and clear pattern of expression in epithelioid mesothelioma 
in both the nucleus and cytoplasm, while in other cancers it appears to be weakly 
staining and restricted to small focal sites [23, 24, 31-33] ; 
1.4. Wilm’s tumor 1 (WT1) is another well used marker in identifying mesothelioma. 
This marker is generally used to discern between mesothelioma and 
adenocarcinoma, as it shows to have a positive staining in as high as 90% of 
mesotheliomas and in none of adenocarcinomas of the lung [24]. On the other 
hand, this immunostaining test has no use in discerning cancer type between 
mesothelioma and serous carcinoma, since both of the tumors are markedly 
positive for WT1. 
2. negative markers: 
2.1. carcinoembryonic antigen (CEA) is one of the first markers used for differential 
diagnosis of mesothelioma from adenocarcinoma, since CEA shows to be positive 
in almost 80% of adenocarcinoma of the lung, while is reported to be negative in 
about 100% of mesothelioma [24, 34]. Conversely, CEA has little use in 
discriminating mesothelioma from cancer like renal cell carcinoma and serous 
carcinoma, since these two last tumors show to have a negative immunostaining 
for the CEA; 
2.2. B72.3 is a monoclonal antibody that stains positively in a wide variety of 
adenocarcinomas (lung, ovary, and peritoneum), while is reported to not stain in 
epithelioid mesothelioma. Hence, B72.3 is one of the most preferentially used 
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markers in discriminating between epithelioid mesotheliomas and 
adenocarcinomas [35]; 
2.3. MOC-31, a monoclonal antibody that recognize specifically Ep-CAM, is 
considered to be one of the most effective negative marker for mesothelioma when 
differential diagnosis is required between mesothelioma and adenocarcinoma of 
the lung and serous carcinoma of the ovary. On the other hand, MOC-31 has little 
use for discriminating mesothelioma from renal cell carcinomas [36]. 
3. Ber-EP4 has a controversial behavior in immunostaining between mesothelioma and 
other tumors, being positive in a range from 30% and 100% in various carcinomas and 
adenocarcinomas, while mesotheliomas can be positive to Ber-EP4 stain in as much as 
one third, even if it appears to be weak and focal. Then, a positivity to this test cannot 
exclude a diagnosis of mesothelioma, but it is common practice to accept a negative 
diagnosis of mesothelioma if the reactivity of this marker is wide and intense [37].  
  
At the present immunohistochemistry staining is used to obtain a diagnosis of malignant 
pleural mesothelioma excluding other neoplasms. Hence, there are no certain positive 
markers that identify by themselves the disease, but the diagnosis is always performed 
using different panels of immunomarkers, which stain differentially in different tumor.  
In conclusion, the most effective positive markers for mesothelioma are reported to be 
calretinin, cytokeratin 5/6 and WT1, while most important negative markers are CEA, 
MOC-31, Ber-EP4 BG-8 and B72.3. Between the mesothelioma subtypes the most 
accurate immunohistochemical diagnosis is represented by the epithelioid subtype, while 
sarcomatoid mesothelioma is reported to be the most difficult to discriminate, because its 
similarity with sarcoma and pulmonary sarcomatoid carcinoma. 
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What is been exposed here raises two main aspects about malignant pleural mesothelioma 
diagnosis: a) despite all the advances in imaging technologies and supports of 
immunochemical staining in determining the nature of the disease, diagnosis for malignant 
pleural mesothelioma remains a complex process; b) since there are no precise and 
unequivocal clinic-pathologic guidelines, it is necessary to develop a system that will help 
clinicians in recognizing the disease with higher certainty and earlier in time. 
1.3.5. STAGING 
As with all malignancies, proper staging is crucial in malignant pleural mesothelioma 
for rational treatment planning. Over the years, many staging systems have been proposed. 
The most widely accepted is the TNM-type system of the International Mesothelioma 
Interest Group (IMIG) [38]. 
In brief, malignant pleural mesothelioma is classified into four stages. Each stage 
describes how far the mesothelioma has spread from its point of origin in the pleura. 
Stages I and II are considered early-stage mesothelioma. Stages III and IV are considered 
late, or advanced-stage mesothelioma. 
Classification and descriptions of each stage are reported as follows: 
Stage I includes lymph node-negative subjects with minimal tumor confined to the 
parietal pleura (Stage Ia) or with minimal visceral pleural involvement (Stage Ib). Subjects 
in Stage I show to have the best prognosis, since the disease is more responsive to 
treatment, because its localization to the pleura. A common curative surgery used for Stage 
I subjects is the extrapleural pneumonectomy (EPP). 
Stage II includes lymph node-negative subjects with confluent superficial tumor on all 
pleural surfaces or involvement of the diaphragmatic muscle or lung parenchyma. Subjects 
in Stage II show to have a more favorable prognosis than those diagnosed with an 
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advanced stage. Stage II subjects are still eligible for potentially curative surgery, like the 
pleurectomy with decortication (P/D). 
Stage III is the most common presenting stage and includes subjects with metastasis to 
hilar (N1) or ipsilateral mediastinal (N2) lymph nodes, or those with extension of tumor 
into the soft tissues of the chest wall, the endothoracic fascia, mediastinal fat or 
pericardium (T3 tumor). The prognosis of subjects diagnosed with Stage III is more 
favorable than Stage IV. Successful curative surgery may extend a Stage III subject’s life 
expectancy beyond 16 months. 
Stage IV includes subjects who have locally advanced tumor invading the spine or ribs, 
the chest wall extensively, transdiaphragmatic spread, or contralateral pleural spread. 
Subjects with Stage IV disease also may have contralateral or supraclavicular lymph node 
involvement (N3) or distant metastases. The average survival rate for Stage IV subjects is 
12 months after diagnosis. Stage IV subjects do, however, have treatment options 
available. Palliative treatment can help ease pain and discomfort caused by advanced-stage 
mesothelioma.  
1.4. OTHER CAUSES OF MALIGNANT PLEURAL 
MESOTHELIOMA BESIDE ASBESTOS 
1.4.1. RADIATION THERAPY 
Malignant pleural mesothelioma cases are known to occur in subjects who underwent to 
thoracic and/or abdominal radiotherapy or received intravenous treatment with Thorotrast 
[39, 40]. The latency of this mesothelioma has been calculated approximately in 20-30 
years after radiation exposure [41, 42]. In children who underwent radiotherapy as 
treatment for Wilms’ tumor, the only causal factor present and ascribable to mesothelioma 
development was ionizing radiation. [43]. Ionizing radiations were shown to cause 
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malignant mesothelioma even in experimental studies in rats [44]. Exposure to Thorotrast 
explains a minimal proportion of MPM occurring in Italy each year (1.7-4.7%). 
1.4.2. GENETIC PREDISPOSITION 
Familiar predisposition to malignant pleural mesothelioma is reported in the literature. 
The study of familiar clustering might enlighten a possible causal factor based on 
individual genetic susceptibility to development of the disease. At any rate, interpretation 
of familiar clustering has to consider a possible common exposure to asbestos of the 
subjects under study before claiming a genetic susceptibility [45, 46]. In the study 
performed by Ascoli et al. on 1954 cases of malignant pleural mesothelioma collected 
between 1978 and 2005 in three different regions of Italy, the asbestos exposure was 
confirmed for the major part of the cases, while a familiar causal factor was reported to 
account for 1.83% of the entire population. Even if the percentage of the familiar cluster is 
low, it is possible to speculate a genetic origin for malignant pleural mesothelioma. In 
addition, among entire asbestos exposed population only a small percentage show to 
develop malignant pleural mesothelioma. Based on these evidences, some studies, in 
particular in Finland and Italy, had evaluated the existence of a relationship between 
mesothelioma risk and genetic polymorphisms, in particular genes of the stress oxidative 
response and DNA repair mechanism, suggesting an interplay of these polymorphisms in 
the risk of developing mesothelioma. The risk in subjects with these polymorphisms seems 
to be 2/4 times higher in comparison to non-carrier subjects [47-49]. Recently, genetic 
susceptibility has been strengthen by various study on BAP1, an oncosuppresor gene often 
associated to different cancers [50]. Inactivating somatic mutations has been found in 12 
tissue pleural samples affected by malignant pleural mesothelioma on 53 total specimens 
(23%) [51]. Similar findings have been found in other two studies, in which inactivating 
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somatic mutations showed to be present in 12 cases of malignant pleural mesothelioma of 
the pleura on 68 total cases, accounting for the 18%, and in 8 mutated cell lines on 25, 
equal to 32% [52]. Since in both the last two described studies asbestos exposure was 
frequently confirmed, it has been hypothesized the presence of somatic mutations in BAP1 
and asbestos exposure might concur to malignant pleural mesothelioma development [51].  
1.4.3. VIRAL INFECTION 
The first suggestion of a relationship between malignant pleural mesothelioma and viral 
infection of SV40 virus traced back to 1994 [53]. Carbone and others observed the 
presence of SV40 in the majority of studied cases, and concluded that its presence was a an 
essential phase in inducing the disease. After several years of debating, particularly 
focused on identifying and confirming the presence of SV40 DNA in malignant pleural 
mesothelioma samples, recent studies do not confirm this association between virus 
presence and onset of the disease [54]. In addition, no association between antibody 
response and malignant pleural mesothelioma has been observed in prediagnostic 
mesothelioma serum samples [55]; or presence of SV40 DNA in a large population study 
had not been found [56]; neither SV40 RNA had been found in malignant pleural 
mesothelioma cells [57].  
1.5. MECHANISMS OF ASBESTOS CARCINOGENICITY 
IN MALIGNANT PLEURAL MESOTHELIOMA  
Two important characteristics related to asbestos fiber carcinogenicity are dimensions 
and surface properties. Experimental studies showed that fibers longer than 5 μm and 
thinner than 0,1 μm have the higher potential to cause MPM. In particular the early studies 
by Stanton [58] reported the highest frequency of MPM for fibres longer than 8 μm and 
thinner than 0,1 μm. However, very short fibres have been detected in pleural and lung 
 22 
 
samples of patients thus a possible role also of fibres shorter than 5 μm cannot be excluded 
[59]. 
The surface activity of fibres is influenced by numerous factors such as crystal 
structure, chemical composition, origin of the mineral and metal ions contaminants. In 
particular, iron ions seem to be the catalytic site for the generation of reactive oxygen 
species (ROS) and free radicals. 
Thin fibres can reach terminal bronchioles and alveoli, where alveolar macrophages can 
phagocyte the fibres shorter than 14-25 μm. Longer fibres have instead the ability to 
damage macrophages hindering (“frustrated phagocytosis”) one of the main fiber removal 
mechanism and also leading to the release of ROS.  
Bio-persistent fibres (that is fibres neither phagocytised nor altered by physical-
chemical actions) may pass through the bronchial epithelium and reach the pleura, the 
peritoneum and other locations where they can interact with target tissue cells (lung 
epithelium, mesothelium, interstitial fibroblasts) for very long time [60, 61].  
Chrysotile and amphiboles have different estimated lifetime, with shorter period for the 
first than the amphiboles group. It has been estimated a period of about 9 months to 
dissolve a fibre with a diameter about 1 μm, whereas smaller particles with 0.1 μm might 
be totally dissolved in only weeks [62]. 
The mechanisms of malignant transformation is still incompletely understood. MPM is 
clinically evident after an average period of 30 or more years during which a complex set 
of genetic and molecular alterations take place. 
The pathogenesis of malignant pleural mesothelioma has been studied by cytological 
analysis to understand if characteristic abnormal karyotypes are present. Many different 
abnormalities, like extensive aneuploidy and structural rearrangements, have been 
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described. The most common changes are the loss of chromosome 22 [63] and structural 
rearrangement of 1p, 3p, 9p,and 6q [64].  
Based on experimental studies, at least six peculiar features of a malignant tissue in 
active and uncontrolled growth have been reported in MPM and are briefly described 
(Figure 2). 
1. Growth Advantage: malignant mesothelial cells show to grow in non-regulated 
manner via autocrine mechanism, in which mesothelioma cells might produce 
themselves growth factors needed for proliferation. Growth occurs in response to 
many different stimuli, such as platelet-derived growth factors (PDGFs) [65], 
epidermal growth factor (EGF) [66], transforming growth factors β (TGFβ) [67], and 
Wnt protein pathway [68].  
2. Immortalization by the Action of Telomerase: generally cell division is limited in time, 
this mechanism is controlled by length of telomeres. It has been shown that 
telomerases are expressed in the majority of mesothelioma cells, thus allowing the 
cells to continue proliferation, becoming immortalized. Immortalization brings about 
to loss of genomic region and aneuploidy [69]. 
3. Absence of Tumor-Suppressor Genes: usually cells avoid to become cancerous cells by 
the activity of genes called tumor-suppressors. In mesothelioma some important 
tumor-suppressors gene products are missing. In particular, p16 and p14 are 
commonly absent, and their lack affects the Rb and p53 pathway, which is important 
in blocking uncontrolled tumor growth [70, 71]. 
4. Induction of Antiapoptotic Processes: on the other hand cells are doomed to die 
because of the action of apoptotic processes, which lead to the activation of a signal 
cascade by the release of caspases after binding on membrane receptors signal 
molecules such as TNF, TNF-related apoptosis-inducing ligand (TRAIL), and Fas 
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ligand. In mesothelioma cells this apoptotic processes are blocked by the activity of 
Bcl-xL, an antiapoptotic molecule often present in tumors.  
5. Increased Angiogenesis: another important factor for the maintenance of uncontrolled 
growth is the ability of the cancerous cells to obtain nutrients in large amount. To 
fulfill this necessity cancers are able to lead formation of new blood vessels. 
Malignant pleural mesothelioma cells produce a wide range of angiogenic factors, 
among the other the vascular endothelial growth factor (VEGF). Animal models 
clearly elucidate the importance of VEGF, in fact in study were this molecule is absent 
mesothelioma growth results slower [72]. In addition, increase in vascularity is often 
associated to a worsening of the prognosis in mesothelioma subjects compared to 
those in which neo-formation of blood vessels is lower [73]. 
Figure 2 Key biologic features of malignant pleural mesothelioma. 
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6. Matrix Interactions: malignant pleural mesothelioma exists in a collagenous 
environment, and it is likely that its growth is related to its interactions with and 
regulation of this environment. Malignant pleural mesothelioma cells make collagen, 
and the prognosis of mesothelioma appears to be related to the expression of matrix 
metalloproteinases. Malignant pleural mesothelioma tumors induce responses from 
their hosts. Chronic inflammation occurs, manifested by the presence of inflammatory 
cells and cytokines. The inflammation is due both to the asbestos and to the malignant 
process itself. The host also commonly mounts a weak antitumor immune response to 
undefined mesothelioma proteins as well as to overexpressed common proteins, such 
as p53. 
All these mechanisms, however, have little specificity and can be activated by a 
multitude of triggers, thus limiting our capability to provide the groundwork for the 
development of targeted biomarkers and prevention strategies. The lack of tumor 
biomarkers for diagnosis and medical survey plays a fundamental role for the development 
of a universally accepted therapeutic approach and a clearer understanding of the major 
molecular pathways of malignant pleural mesothelioma is still needed to establish 
diagnostic, therapeutic and prevention methods [74].  
The role of inflammation in causing neoplastic transformation of cells [75] is relevant 
for mesothelial cells too [76-78]. Overall the processes and the alterations that favor the 
development of the malignant pleural mesothelioma after asbestos fibres interaction with 
target cells and with macrophages can be summarized as follows; microenvironment with 
persistent inflammation and chronic oxidative stress; direct and indirect genotoxic 
alterations; chromosomal alterations; epigenetic alterations. These alterations cause the 
activation of the pathways regulating cell cycle, inactivation of oncosuppresor genes, 
resistance to apoptosis; acquired genomic in stability and neoangiogenis. 
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1.6. MICRORNA  
microRNAs are a relatively recent class of translational regulator. The first findings of 
small non-coding oligonucleotide sequence are traced back to 1993 [79], when Lee et al. 
published a study about C.elegans development. In this study has been reported that an 
already known fragment of 700 bp, called lin-4, was able to control timing in nematode 
larval development without characteristic start and stop codons; therefore without coding 
for a protein. Once transcribed, lin-4 is folded in a 61 nt long hairpin conformation thanks 
to the complementarity of its 5' and 3' ends. The hairpin is later cleaved by proteins 
complex to produce a shorter sequence of 22 nt, which in turn has complementary sites in 
the 3' UTR of the lin-14 gene. The bound of lin-4 gene product to lin-14 mRNA leads to a 
significant reduction of the LIN-14 protein, without any change in the total amount of the 
lin-14 mRNA.  
Between the discover of lin-4, in 1993, and another similar small non-coding RNA takes 
roughly 7 years. Indeed, only in 2000 a study disclose the existence of let-7, a 21 nt long 
non-coding RNA with a similar timing function in C.elegnas development [80]. 
Conversely to lin-4, the newly called microRNA let-7 was found to be highly conserved 
across species from nematode to human. Because of this, the existence of other similar 
RNAs has been hypothesized in other organisms, included human. Indeed, few months 
later let-7 has been detected at different expression levels in many different tissues and 
organism [81]. 
let-7 shows to have a sequence highly conserved not only among species, but also 
compared to other miRNAs. This highly conserved sequence is called seed sequence. In 
human 14 miRNAs have been found to share the same seed sequence of let-7, and it is 
possible to group all of them in a family, in which each different members of the let-7 
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family can act in redundant manner, cooperating all together to control the same miRNAs 
target [82-84].  
Since 2000, discovery of these ≈22 nt long non-coding RNA has increased exponentially 
every year (Figure 3), and, together with new miRNAs, our knowledge about their 
numerous functions and implications in various cellular pathways, such as control of the 
cell cycle and proliferation [85], cell death [86], signaling pathways [86-88], development 
[89], and differentiation [90] in physiologic conditions. 
More recently it has been proposed that miRNAs may also be involved in several 
diseases; among them an important role is played in regulation and modulation of gene 
expression in tumors, including breast, colon, prostate and lung cancers. In neoplasms, 
miRNAs seem to behave as repressor of tumor suppressor genes or activator of oncogenes, 
and to be aberrantly in these diseases. Because of their characteristics, miRNAs have been 
proposed to be used as early biomarkers for cancers and also as a predictor factor of patient 
survival. Identification of specific miRNA signature not only may be helpful for diagnosis, 
but would be possible to use miRNAs as target for personal and molecular drug treatment. 
1.6.1. MICRORNA BIOGENESIS 
In human miRNAs are generally localized within intronic regions of genes or dispersed 
in non-coding transcripts, rarely miRNAs can be found in exonic regions. Another typical 
characteristic of miRNAs localization is the organization in polycistronic units, in which 
different miRNA genes clustered in close proximity to each other. Usually, this clustered 
miRNAs are transcribed as a single polycistron containing information for all the miRNAs 
that are singularly post-transcriptionally regulated [91].  
Often transcription of intronic miRNA genes are regulated by the same promoter of the 
host gene. On the other hand, some miRNA genes show to have multiple transcription 
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starting sites with intronic promoters distinct from promoter of their host gene. In both 
cases, once transcribed, intronic miRNA genes do not interfere with maturation of their 
host mRNA [92]. Conversely, maturation of a newly transcribed exonic miRNA genes is 
proven to destabilize the host mRNA [93].  
In the nucleus, the transcriptional machinery of miRNAs is normally run by RNA Pol II 
and its associated transcription factors, together with epigenetic regulators (Figure 4). 
Then, some transcription factors [94], like MYC, ZEB1
 
and ZEB2, and epigenetic control 
[95], such as DNA methylation and histone modification concur to the regulation of 
miRNA expression. Once miRNA genes are transcribed their primary miRNAs, or pri-
miRNAs, are long more than 1 kb and show their characteristic hairpin structure, 
containing the mature miRNA sequences. Generally, complementary sequences of the 
same pri-miRNA anneal to form the stem of the hairpin, long 33-35 bp; at the top of the 
Figure 3 The growth of the number of sequences deposited in miRBase, and the 
number of papers in PubMed that contain the word “microRNA” in title, keywords, 
abstract (miRBase R20, June 2013)[http://www.mirbase.org/blog/2014/03/high-
confidence-icrornas/] 
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stem a single-stranded RNA sequence gives rise to the loop of the structure, while at the 3' 
and 5' ends lay two single-stranded terminals. Then, the maturation process starts with pri-
miRNA cleavage by Microprocessor complex (Figure 4), consisting of two proteins 
Drosha and DRGC8. Drosha is a nuclear RNase III that act specifically on pri-miRNA 
thanks to its C-terminal double-strand RNA binding domain (dsRBD) and two 
intramolecular RIIIDs, that dimerize to form one cleavage site for cutting pri-miRNA at its 
3' and 5' termini. Since the only Drosha dsRBD isn’t sufficient for stabilizing pri-miRNA, 
DGCR8 is necessary. This protein has two dsRBD close to C-terminal helix and the site of 
interaction with Drosha. In addition DGCR8 has an important haem-binding domain 
required for interaction with ferric ions, necessary for an efficient pri-miRNA processing. 
Once Microprocessor complex is bound to the pri-miRNA, Drosha is able to recognize 
a region 11 bp approximately far away from the basal junction, where the pri-miRNA 3' 
and 5' termini are single-stranded, and 22 bp from the apical junction in the middle of the 
single-stranded loop. These two regions contain three highly conserved motifs, UG and 
CNNC motifs in basal junction and UGUG motif in the terminal loop. The interaction 
between Microprocessor complex is still not totally clear, but deficiency in Drosha causes 
lethality early in embryogenesis, and lack of DGCR8 in knockout mice arrests 
development and knockout embryonic cells have impaired proliferation and differentiation. 
Therefore, the efficiency of Microprocessor complex is determinant for regulation of 
miRNAs abundancy and activity. Due to their importance, Drosha and DGCR8 are fine 
regulated. Actually, while DGCR8 stabilizes Drosha by protein-protein interactions, 
Drosha acts by enzymatic cleavage on the second exon of DGCR8 mRNA. Thus, this 
cross-regulatory loop enables the homeostatic maintenance of Microprocessor activity and 
is deeply conserve throughout the animal kingdom. Other regulations of Microprocessor 
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activity are determined by post-translational modification, that regulate protein stability, 
nuclear localization and processing activity [96]. 
After pri-miRNA is transcripted and processed by Microprocessor complex in the 
nucleus, it becomes pre-miRNA that is exported to the cytoplasm for its final maturation 
(Figure 4). 
Pre-miRNAs are exported through the nuclear membrane pores by protein transport 
complexes formed by EXP5 and the GTP—binding protein RAN (Figure 4). So, by GTP 
hydrolyzation pre-miRNA is released into the cytoplasm and captured by Dicer, an RNase 
III type endonuclease. C-terminal of Dicer contains two RIIIDs repeated in tandem, 
forming a catalytic core similarly to those in Drosha (Figure 5). The N-terminal helicase of 
Dicer recognizes the pre-miRNA loop, increasing the processing of certain pre-miRNAs; 
while PAZ domain binds preferentially the 3' terminus of pre-miRNAs at two-nucleotide-
long overhang left by Drosha cleavage. The recognition and binding specificity make 
possible to Dicer to produce the pre-miRNA, which are 22-25 nucleotides long. In 
addition, in mammals and flies, Dicer could bind the 5’ end of the pre-miRNA and cleaves 
it at ≈22 nucleotides away from the terminus. 
The small RNA duplex produced by Dicer is then loaded onto an AGO protein to form 
an effector complex called RNA-induced silencing complex (RISC), that becomes active 
after unwinding of the miRNA duplex and removal of the passenger strand (Figure 5). 
AGO proteins preferentially choose the guide RNA strand (the actual active miRNA) on 
the base of the relative thermodinamical stability of small miRNA duplexes at their 5’ 
monophosphate. In facts, the most unstable 5’ terminus is typically selected as the guide 
strand, especially when the 5’ terminus starts with an U or an A, that are tightly bound by 
the 5’-phospahate- binding pocket present in AGO proteins. While, passenger miRNA is 
removed easily when the duplex has central perfect matches. More often, small miRNA 
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duplexes show central mismatches, then miRNA unwinding occurs without cleavage of the 
passenger. As the selection of the guide strand doesn’t follow a strict process, the 
passenger strand could become active, even if its relative abundancy is lower than that of 
the guide strand. 
Once pre-RISC is activated to functional RISC, it can affect mRNA translation by two 
different mechanisms. a) When miRNA loaded onto AGO protein shows to have a perfect 
complementarity to the target 3'-UTR mRNA, the slicer activity of AGO2 is able to cleave 
the target between the positions 10 and 11 of the mRNA. Thus, the cleaved mRNA is 
rapidly degraded. b) In most cases miRNA and its target do not have a perfect 
complementarity, then RISC starts an inhibitor cascade. Firstly, mRNA translation is likely 
blocked by the presence of the miRNA. Then, AGO-binding partners are summoned to the 
RISC-mRNA complex, and the target is deadenylased and decaped at its 5’. In the end, a 
5’-to-3’ exonuclase is enabled to degrade the mRNA. On the basis of this second inhibition 
process, it has experimentally described that different miRNA members of the same seed 
sequence family are able to interfere with translations of different target mRNAs, thus 
production of a protein is under control of many different miRNA, which concur to the 
regulation of its translation. 
 In addition to this regulation, a single mRNA may possess multiple sites that are 
recognized by miRNA members of different seed family.  
 
 
 32 
 
 
Figure 4 Nuclear events in the miRNA biogenesis pathway. a | Schematic model of 
miRNA transcription by RNA polymerase II (Pol II), nuclear processing by the 
Microprocessor complex (comprising Drosha and DGCR8) and export by exportin 5 
(EXP5) in complex with RAN•GTP. b | Examples of how miRNA transcription and primary 
miRNA (pri-miRNA) processing are regulated. p53, MYC and myoblast determination 
protein 1 (MYOD1) transactivate the miR-34, miR-17 and miR-1 clusters, respectively. 
MYC transcriptionally suppresses the miR-15a cluster, and ZEB1 and ZEB2 
transcriptionally suppress the miR-200 cluster. Various post-translational modifications of 
Drosha and DGCR8 control the activity and/or localization of these proteins; the protein 
responsible for the modification, and the effect on Drosha or DGCR8, is shown in each 
case. The RNA-binding protein TAR DNA-binding protein 43 (TDP43) also interacts with 
Drosha. RNA-binding proteins, such as p68, p72, KH-type splicing regulatory protein 
(KSRP), heterogeneous nuclear ribonucleoprotein A1 (HNRNPA1) and LIN28, also 
regulate pri-miRNA processing. Finally, ADAR1 and ADAR2 mediate RNA editing from 
adenosine to inosine, which interferes with Drosha processing. c | Domain organization of 
Drosha, DGCR8 and EXP5 in humans. d | Structure of EXP5 (pink) complexed with 
RAN•GTP (violet) and pre-miRNA83. The position of the two-nucleotide-long 3ʹ overhang, 
which interacts with a basic tunnel-like structure on EXP5, is indicated with a circle. aa, 
amino acid; Ac, acetyl; dsRBD, double-stranded RNA-binding domain; GSK3β, glycogen 
synthase kinase 3β; HBD, haem-binding domain; HDAC1, histone deacetylase 1; HEAT, 
huntingtin, EF3, PP2A and TOR1; MECP2, methyl-CpG-binding protein 2; NLS, nuclear 
localization signal; P, phosphate; RIIID, RNase III domain; R-SMAD, receptor-activated 
SMAD. Part d from Okada, C. et al. A high-resolution structure of the pre-microRNA 
nuclear export machinery. Science 326, 1275–1279 (2009). 
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Figure 5 See caption Page 34. 
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Figure 5 Cytoplasmic events in the miRNA biogenesis pathway. a) Schematic model of 
Dicer-mediated processing and Argonaute (AGO) loading. Dicer interacts with a double-
stranded RNA-binding domain (dsRBD) protein (TAR RNA-binding protein (TRBP) in 
humans and Loquacious (Loqs) in flies). Following Dicer processing, the RNA duplex is 
released and subsequently loaded onto human AGO1–4. A heat shock cognate 70 
(HSC70)–heat shock protein 90 (HSP90) complex hydrolyses ATP to load the RNA duplex. 
The ‘passenger’ strand is discarded and the ‘guide’ (mature) microRNA (miRNA) remains 
in one of the AGO proteins. b) TRBP and AGO proteins are subject to post-translational 
modifications, which influence their ability to regulate Dicer processing, RNA-induced 
silencing complex (RISC) formation and miRNA activity. miRNA tailing by TUT4 and 
TUT7, RNA methylation by BCDIN3D, RNA editing by ADAR1, a decrease in RNA 
stability mediated by MCP-induced protein 1 (MCPIP1) and Ser/Thr protein kinase/ 
endoribonuclease IRE1α also inhibit Dicer processing. A decrease in miRNA stability can 
downregulate miRNA activity. c) Domain organization of Dicer, TRBP and AGO2 in 
humans. d) Cryo-electron microscopic reconstruction of human Dicer108. e) Structure of 
human AGO2 and the guide RNA (red)136. The 5ʹ monophosphate of the guide RNA is 
tightly anchored to the 5ʹ-phosphate-binding pocket at the interface between the MID 
(middle) and PIWI domain. 4PH, type I collagen prolyl 4-hydroxylase; aa, amino acid; 
EGFR, epidermal growth factor receptor; KSRP, KH-type splicing regulatory protein; L, 
linker; MAPKAPK2, MAPK-activated protein kinase 2; N, amino-terminal domain; OH, 
hydroxyl; P, phosphate; P-body, processing body; PARP, poly(ADP-ribose) polymerase; 
PAZ, PIWI–AGO–ZWILLE; RIIID, RNase III domain. Figure part d from REF. 108, 
Nature Publishing Group. Part e from Schirle, N. T. & MacRae, I. J. The crystal structure 
of human Argonaute2. Science 336, 1037–1040 (2012).  
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1.7. MESOTHELIOMA AND MIRNAS 
As miRNAs are relatively a new discovery in molecular biology, great efforts are 
especially focused in studying their role in regulation of gene expression, and especially as 
oncogenic molecules. On the basis of their ability of interfering with gene expression, 
miRNAs are involved in many important cellular processes, like proliferation, 
development, differentiation, apoptosis, and stress response. Thus, miRNAs show to have 
aberrant expression in many different cancers, hence they can play an important role in 
oncogenesis. An important characteristic of miRNAs is their specificity of expression in 
normal and cancerous tissues, due to this miRNAs might be used as biomarkers for early 
detection and diagnosis of diseases, as well as to differentiate diagnosis between a primary 
or secondary neoplasm forms. In addition, miRNAs are present not only in the site of their 
production, but from there they are able to spread into in many different human body 
fluids, like in blood, exhaled breath condensate (EBC), saliva, and urine. 
Due to their short sequences, miRNAs are much more stable and resistant to 
degradation by RNases than mRNA, hence analysis of miRNAs expression are more 
reliable and reproducible than genes expressions analysis. 
To extensively study miRNAs expression profile two technologies are generally used: 
microarray analysis and quantitative real-time PCR (RT-qPCR). The first is a useful high-
throughput method that allows quantification of various miRNA in a single reaction 
containing specific probes for all the target miRNAs. In addition, microarrays use low 
volume and amount of starting samples. On the other hand, microarray results need a 
validation, as quantification reads are not sensitive as RT-qPCR. This second technology 
is, in fact, highly sensitive and able to quantify in high fidelity the amount of a specific 
miRNA. 
 36 
 
To date, only a few studies have been performed on relationships between miRNAs 
deregulation and malignant pleural mesothelioma. One of the first studies about miRNA 
differential expression [97] found a subset of deregulated miRNAs in frozen malignant 
pleural mesothelioma samples collected during surgery, compared to normal human 
pericardium. In addition, some of these miRNAs resulted to be specific for each 
morphological subtype of malignant pleural mesothelioma, suggesting a scope of miRNAs 
not only in diagnosing malignant pleural mesothelioma, but also in detecting subtype, 
making their use available as prognostic factors and choice of treatment. In the same 
article, researchers reported a target genes analysis performed by web-based computational 
approach to screen predicted target of the deregulated miRNAs. They concluded that 
among those genes deregulated by miRNAs they found some of the most affected genes in 
malignant pleural mesothelioma, like CDKN2A, NF2, JUN, HGF and PDGFA [97]. 
Other fascinating aspects of the use of miRNAs in medicine, in addition to diagnosis 
markers, are their possible role as predictors of prognosis and cancer therapeutics. 
Pass et al. [98] reported a differential regulation of hsa-miR-29c-5p among different 
histo-morphological type of malignant pleural mesothelioma. In this study, 129 surgically 
treated snap-frozen malignant pleural mesothelioma tissues, 9 malignant pleural 
mesothelioma cell lines and three normal mesothelial cell lines were tested by miRNA 
microarray platform, and further validate with RT-qPCR. Conclusion stated that hsa-miR-
29c-5p has an higher expression in the epithelial form of the disease than in non-epithelial 
malignant pleural mesothelioma, resulting in a more favorable prognosis and a longer 
median survival of epithelioid-affected patients. 
Recently, cell-free miRNAs in plasma of MPM patients has been investigated by 
several research groups [99-102] but those investigations have been done only on a few 
patients and/or for a few candidate miRNAs, and results need confirmation. 
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1.8. EXHALED BREATH CONDENSATE AND BLOOD 
Since miRNAs are stable and resistant to RNases-mediated degradation, and do not 
show any particular post-transcriptional modifications, they are thought to be good 
molecules to use in diagnosis of many different disease. Moreover, miRNAs have been 
found not only in cell cytoplasm, but also in extracellular environment such as plasma, 
serum, saliva and urine [103]. Some studies have positively correlated the level and 
composition of these biological matrices with diseases or other pathological conditions 
[103, 104]. On the base of these findings, the investigation of miRNAs as specific 
biomarker of pathological conditions is intriguing. By definition, a good and useful 
biomarkers has to be characterized by eager of accessibility, non-invasive procedures of 
extraction, detection of a specific disease earlier than the symptoms occurrence. Also 
proteins might be used as good biomarkers [105], but differently from miRNAs, they show 
an higher complexity of composition due to their many post-translational modifications, in 
addition proteins have a low abundance in most of the biological samples and this 
influences greatly the reliability of their use as biomarkers. However, miRNAs could 
present the same obstacles, but, conversely to proteins, methods like PCR and other 
amplification strategies might overcome this kind of problems, making miRNAs much 
easier to detect and to quantify with high-fidelity.  
In this project we have chosen two biological matrices from which isolate extracellular 
miRNAs: blood and exhaled breath condensate (EBC).  
Previous studies demonstrate that miRNAs are present and could be detected in blood 
[103, 104]. Their release out of the producing cells have been hypothesized to follow three 
possible mechanisms: passive release from cells[106]; active secretion in response to 
different stimuli as protein-miRNAs complex [107]; and active release through 
microvescicles [108]. 
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 Recently, EBC has been used in clinical studies as a biological matrix where miRNAs 
can be analyzed and quantified by qPCR to investigate their role in non-small-cell lung 
cancers [109]. EBC presents the advantages to be easily collected in a non-invasive way 
causing no discomforts in patients of any age and any health status. In addition, EBC might 
represent a potential surrogate of the lung environment and the lower respiratory tract, 
avoiding the need of tissue removal from the same body district. 
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2. AIM OF THE STUDY 
Understanding the molecular mechanisms responsible for malignant pleural 
mesothelioma development, as well as finding a non-invasive disease biomarker, would be 
fundamental to better monitor and to early diagnose malignant pleural mesothelioma in 
affected patients and previously exposed subjects, enhancing prognosis and therapy. 
Malignant pleural mesothelioma diagnosis is not easy, as it is often hard to distinguish 
between inflammatory/reactive diseases and malignant forms. In addition, the long latency 
between asbestos exposure and disease onset, makes the follow up of exposed individuals 
quite challenging. 
MiRNA expression levels vary greatly among tissues, and it is believed that dysregulation 
of miRNA can contribute to cancer development. Therefore, miRNA expression in 
malignant pleural mesothelioma, might have a central role in influencing oncogenic 
pathways, particularly in EBC produced from pulmonary environment cells, as well as in 
plasma. Therefore, it is of great interest the analysis of miRNAs as a fundamental part of 
mechanisms of action mesothelioma-associated gene expression which may have relevance 
in etiology, progression and treatment of malignant pleural mesothelioma.  
Specific aims of this project are: 
Aim 1: Determine whether a specific miRNA signature (in plasma or EBC) may help to 
discriminate between malignant pleural mesothelioma patients and patients affected by 
other pulmonary diseases, among patients presenting at the Thoracic Surgery Unit with a 
diagnosis of pleural effusion.  
Aim 2: Determine whether a specific miRNA signature (in plasma or EBC) may help to 
discriminate between Malignant Pleural Mesothelioma (MPM) patients and healthy 
subjects with a Past Exposure Asbestos (PEA).  
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Aim 3: Evaluate a possible correlation between miRNAs in EBC and plasma.  
Aim 4: Estimate sensitivity and specificity of altered miRNAs using ROC curves. 
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3. MATERIAL AND METHODS 
3.1. STUDY POPULATION 
The study population includes 23 malignant pleural mesothelioma (MPM) cases (group 
A), 9 subjects with pleural effusion due to diseases others than MPM (group B) and 19 
healthy subjects occupationally exposed to asbestos (control group C). 
Group A and B subjects have been enrolled among patients presenting at the Thoracic 
and Lung Surgery Unit (Ospedale Maggiore Policlinico Fondazione IRCCS Ca’ Granda) 
with pleural effusions. Each subjects underwent to echo-assisted thoracentesis. Samples of 
pleural fluid were tested by cytology for malignant tumor cells, BK, common germs and 
chemical-physical examination. Same subjects underwent to a further examinations by 
total body PET combined with CT of the thorax, these imaging tests help clinician in both 
preoperative organization and staging of the disease. Video-Assisted Thoracoscopy 
(VATS) was then performed on the basis of the imaging knowledge to obtain tissue from 
the site of pleural effusions. After biopsy, specimens has been analysed histologically to 
describe the ethology of pleural effusion. 23 subjects resulted positive to 
immunohistochemical staining for malignant pleural mesothelioma composed the group of 
Malignant Pleural Mesothelioma (MPM) cases, while subjects with a negative response to 
malignant pleural mesothelioma fell into the group of Non-Mesothelioma (NM) subjects 
(Group B). 
Group C includes subjects presenting at the Occupational Health Unit for clinical 
surveillance due to Past Exposure to Asbestos (PEA). Each subjects underwent to routine 
examinations with Pulmonary Function Testing coupled with DLCO, thorax oblique 
radiography, and Bronco-Alveolar Lavage, to determine quantitatively asbestos exposure 
by counting number of asbestos corpuscles per milliliter.  
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The enrolment period ranges from October 2012 to August 2014. The study has been 
approved by the local Institutional Review Board (“IRCCS Fondazione Policlinico, Ca’ 
Granda”) 
3.1.1. DIAGNOSTIC CRITERIA FOR MALIGNANT 
PLEURAL MESOTHELIOMA 
The diagnosis of malignant pleural mesothelioma was established based on standardized 
criteria following the ReNaM criteria [110]. A subject was classified as MPM when the 
histological examination of paraffin-embedded tissue confirmed a diagnosis of malignant 
pleural mesothelioma; at least one of the following immunohistochemistry test was 
positive: keratin LMW/HMW, vimentin, calretinin, and HMBE-1 and VATS confirmed 
neoplastic lesions in the pleura. 
If none of the above criteria was satisfied the subjects were classified in NM group 
(group B). 
3.1.2. DATA COLLECTION  
After signing informed consent each subjects was administered with a standardized 
questionnaire to collect information about asbestos exposure at work, home and in the 
environment, smoking habits, previous clinical history and demographic data. 
Individual, written, informed consent from each participant and approval from the local 
Institutional Review Board (“IRCCS Fondazione Policlinico, Ca’ Granda” review board) 
had been obtained before the study. All the subjects of the study had been informed about 
treatment of the data and its disclosure to third parties; aim and rationale of the project; 
health risks derived from collection of biological samples; and prospects of use on the 
fringes of biological samples in surplus, also for studies concerning the same aim.  
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After signing informed consent, each subject was interviewed by a trained interviewer 
using a standardized questionnaire (ReNaM questionnaire, appendix A to collect 
information about asbestos exposure at work, home and in the environment, lifestyle 
habits, in particular smoking habits, personal and family clinical history, drug intake and 
demographic data.  
3.1.3. ASBESTOS EXPOSURE EVALUATION  
Once clinical data and occupational information were acquired, an expert panel 
reviewed the diagnostic accuracy of cases after examining complete clinical records, 
including radiology and pathology results and evaluate asbestos exposure. The panel is 
composed of a pneumologist, an oncologist, a pathologist, an occupational health 
physician and an industrial hygienist, according to the national guidelines. 
Asbestos exposure is coded as follows :: 
1. certain occupational exposure:  
subjects who had worked in occupational environment with documented presence/use 
of asbestos. At least one of the following must be reported: explicit declaration of the 
patient; environmental investigations, or reports from supervisors, or administrative 
records, or statements of co-workers, or relative/partner. In addition, subjects with 
occupational exposure Code 2 or 3 showing disease manifestations such as bilateral 
pleural plaques, asbestosis, and/or positive Broncho-Alveolar Lavage have to be 
included in this level. 
2. probable occupational exposure: 
subjects who had worked certainly with/in presence of asbestos for occupational reason, 
but exposure documentation/statement is not available. 
3. possible occupational exposure: 
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subjects who had worked in occupational environment belonging to an economic sector 
in which presence/use of asbestos was generally observed, but no information about 
exposure of subjects is available. 
4. domestic or familiar exposure: 
subjects not occupationally exposed, but exposure due to domestic environment, since 
living with at least one employee assigned to categories 1 or 2. 
5. environmental exposure: 
subjects who had lived in the vicinity of asbestos manufacturing plants (industries, 
mines, etc.) or who had attended regularly environments with presence of asbestos for 
non-occupational reasons. 
6. non-occupational exposure: 
subjects who had used asbestos or related materials for non-professional reasons (use of 
asbestos in furnishings, DIY, home repairs, etc.). 
7. improbable exposure: 
subjects who can be reasonably excluded from any asbestos exposure above "natural 
background" levels, on the basis of complete collected information. 
8. unknown exposure: 
incomplete collected information or insufficient knowledge of subjects do not allow an 
assignment into an exposure category. 
9. to be defined exposure: 
subjects for whom exposure assessment and information are being evaluated by experts 
panel. 
10. unclassifiable exposure: 
subjects who are not and will not be available information (closed case). 
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3.2. BLOOD AND EXHALED BREATH CONDENSATE 
COLLECTION 
Peripheral Blood (9 ml) was collected in tubes containing EDTA (Figure 6 A), 
processed within 3 hours, and centrifuged at 1200  xg for 15 min to separate plasma and 
buffy coat fraction from red cells fraction. After centrifugation, plasma fraction was 
aliquoted in two 2 ml criovials (containing 1500 µl each. Aliquots from the same subject 
were labelled with an unique ID number and stored at –80 °C.  
Exhaled Breath Condensate (EBC) was collected with TURBO-Disposable Exhaled 
Condensate Collection System (DECCS) (Medivac, Parma, Italy) (Figure 6 B). This 
system is disposable as suggested by ERS/ATS guideline to avoid any contamination by 
the presence of disinfectants employed to clean used circuits, or even worst by virus. 
Briefly, subjects were asked to breath into the mouthpiece for 15 min under normal tidal 
volume condition with a nose clip to avoid nose breathing. In addition to avoid salivary 
contamination, the mouthpiece is equipped with a special T-trap, placed right after the 
mouth piece. Depending on patient’s health conditions, collection of EBC could be 
stopped allowing the subject to regain breath or to cough. Samples of EBC were collected 
in a refrigerated tube at 5 °C. Briefly after collection EBC samples were centrifuged at 
3000 xg for 15 min at 4°C. EBC samples were labelled with subject’s ID and stored at – 
80 °C. 
3.3. PROCESSING OF BIOLOGICAL SAMPLE 
To isolate free miRNAs and microvescicles from plasma, an aliquot of 1.5ml per 
subject was thawed on ice; samples were then centrifuged three times at increasing speeds 
(1000  xg, 2000  xg, 3000 xg) for 15 min at 4 °C. After every centrifugation, supernatant 
was decanted into a new tube and centrifuged again to remove cell debris and aggregates. 
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A B 
Figure 6 EDTA Tubes with Centrifuged Peripheral Blood. B TURBO-DECCS System. 
Figure 7 miRNeasy Mini Kit Procedure 
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EBC samples were thawed on ice and spun down at 4°C to collect all the EBC at the 
bottom of the vial. 
Shortly after centrifugation, all plasma and EBC samples were transferred into 
ultracentrifuged tubes (Polycarbonate Centrifuge Bottles-Beckman Coulter) and filled up 
to 10.5 ml total with NaCl 0.9% solution. Ultracentrifugation was performed at 110,000 xg 
for 2h at 4°C to allow sedimentation of microvescicles.  
After ultracentrifugation, supernatant was discarded and tubes were allowed to air dry 
for 2 min. Then, tubes were stored at -20°C.  
3.4. MIRNA PURIFICATION 
miRNAs purification was performed using miRNeasy Mini Kit (Qiagen, Düsseldorf, 
GER)(Figure 7). This method purifies miRNA and other small RNA molecules from 
human biospecimens, such as Exhaled Breath Condensate and plasma. 
 The miRNeasy Mini Kit combines phenol/guanidine-based lysis of samples and silica 
membrane–based purification of total RNA.  
Microvescicles were lysed in the 700 µl of reagent QIAzol Lysis Reagent. QIAzol Lysis 
Reagent is a monophasic solution of phenol and guanidine thiocyanate, designed to 
facilitate lysis of tissues, to inhibit RNases, and also to remove most of the cellular DNA 
and proteins from the lysate by organic extraction. After pipetting and vortexing samples, 5 
µl of external miRNA spike-in were added to each sample. The external miRNA ath-miR-
159a spike-in was then used as normalizer of target miRNAs for following real time PCR 
experiments (see Statistical Analysis); it consists of an oligonucleotide from Arabidopsis 
thaliana added in a known concentration of 1,2 pg/µl for a total of 6 pg. To allow lysis and 
RNases degradation, 140 µl of chloroform were added to separate the homogenate into 
aqueous and organic phases by centrifugation at 12,000 x g for 15 min at 6°C. RNA 
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partitioned to the upper, aqueous phase, while DNA partitioned to the interphase and 
proteins to the lower, organic phase or the interphase. The upper phase (~350 µl) was taken 
and 1 volume of ethanol 70% was added to provide the flow of small RNA molecules 
through the membrane of the miRNeasy Mini spin column, while RNA molecules from 
200 nucleotides upwards remained bound to it. The sample was loaded to a new miRNeasy 
Mini spin column, and 2/3 volume of ethanol 100% were added to wash efficiently away 
phenol and other contaminants by centrifugation at 9,700 x g for 15 s at RT. miRNeasy 
Mini spin column, containing miRNA, were washed with RPE buffer and 80% ethanol by 
repeated centrifugations, and later 20/25 µl of RNases free water were added to the column 
to elute miRNAs. Two aliquots per each samples of EBC and plasma were prepared for 
further Open Array analysis (20 µl Exhaled Breath Condensate and 15 µl plasma) and for 
qPCR validation (5 µl both). 
3.5. MIRNA QUALITY CONTROL 
To assess quality of miRNAs purification, samples were measured by 2100 Bioanalyzer 
(Agilent Technologies, Santa Clara, CA)(Figure 8) using Agilent RNA 6000 Small Kit, 
made to detect a wide range of RNA molecules. 
2100 Bioanalyzer is a capillary electrophoresis instrument based on chips used to 
analyze DNAs, RNAs and proteins. 
The chip is composed by 16 wells, 3 of them are for the gel-dye mix, 1 for the ladder 
ranging from 20 nt to 150 nt, and 12 wells are for samples (1 µl of sample for each well). 
Firstly, he gel- dye mix is loaded and is spread on the bottom of the chip by a syringe, after 
this the other two gel-dye mix are loaded, and finally once the gel is ready the 12 samples 
and the ladder could be loaded. 
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Figure 8 Agilent Technologies 2100 Bioanalyzer. 
Figure 9 Bioanalyzer ladder. 
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Charged molecules, as RNA, were leaded electrophoretically by the voltage gradient 
through the gel on the basis of constant ratio charge-mass. Then, the molecules were 
separated because of their dimension and detected by laser-induced fluorescence. The 
analysis software transformed fluorescence data in electropherogramms and compared 
automatically each sample electropherogramm to the standard ladder (Figure 9) to assess 
concentration, dimension and quality of each sample. 
After quality control, EBC and blood samples, previously purified, were concentrated with 
Concentrator Plus/Vacufuge Plus (Eppendorf, Hamburg, GER) to 1 µl at room temperature 
to obtain desired concentration for reverse transcription and Open Array analysis. Directly 
after concentration, samples were placed on ice. 
3.6. REVERSE TRANSCRIPTION AND HIGH-
THROUGHPUT QRT-PCR  
miRNAs can be reverse transcribed using a reverse transcriptase in combination with 
specific stem-loop primers (Figure 10). Reverse transcriptases are a class of enzymes that 
allow to obtain a copy of complementary DNA (cDNA) starting from an RNA template. 
Since miRNAs are short oligonucleotides, standard random primers are not able to anneal 
as in long mRNAs sequences allowing the following specific real time assay. While, the 
stem-loop primers are designed to extend the 3’ end of the target miRNA producing an RT 
primer/mature miRNA chimera template that can be used as in a standard real time PCR. 
Also, the stem-loop structure in the tail of the primer confers a key advantage to these 
assays: specific detection of the mature, biologically active miRNA.  
Up to 762 miRNAs and controls were reverse transcribed in two separate reactions 
using two RT Primers pool, containing each one a mixture of miRNA-specific stem-loop 
primers for an almost comprehensive coverage of the known miRNoma, consistent with 
Sanger miRBase v14.  
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Since the concentration of miRNA in plasma and EBC was low, a uniformed and 
unbiased amplification was performed starting from 1 ng of total input template, thus all 
the reverse transcribed miRNAs present in original samples were increased significantly, 
making assay sensitivity and miRNAs detection better.  
For the final quantitation step, a polymerase, with its substrates, was added to each 
sample and later loaded on Open Array MiRNA panels (Applied Biosystem, Foster City, 
CA) by AccuFill System (Applied Biosystem, Foster City, CA). The real-time PCR is then 
run on the QuantStudio 12K System (Applied Biosystem, Foster City, CA). 
Briefly (Table 3Table 4), the reactions to reverse transcribe target miRNAs were prepared 
separately in reaction A and B in a 96-wells plate using 0.75 µl of Megaplex RT Primers 
Pool A v2.1 and Pool B v3.0 (Life Technologies, Carlsbad, CA), respectively. Both of the 
two reactions included 0.15 µl of dNTPs 100 mM, 0.75 µl 10X RT Buffer, 0.90 µl of 
MgCl2 25 mM, 0.1 µl of RNases Inhibitor 20 U/µl, 1.5 µl of MultiScribe Reverse 
Transcriptase (Life Technologies, Carlsbad, CA) 50 U/µl. Subsequently, 3.5 µl of miRNA 
sample were added to reach a total volume of ~7.5 µl. Following reverse transcription  
 
Figure 10 TaqMan MicroRNA Assay mechanism. In a first step mature miRNA is 
annealed in specific manner to a looped RT primer and reverse transcribed in cDNA. In 
the second step a normal pair of specific primers are annealed to amplify the miRNA 
target. 
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Table 3 Reagents RT Reaction Mix. 
 
Stage Temperature Time 
40 Cycles 
16° C 2 min 
42° C 1 min 
50° C 1 sec 
Hold 85° C 5 min 
Hold 4° C ∞ 
 
Table 4 RT PCR conditions. 
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consists of 40 cycles at 16°C for 2 min, 42°C for 1 min and 50°C for 1 s, plus one cycle at 
85°C for 5 min and final stage at 4°C.  
After reverse transcription, each reaction required to be pre-amplified in a 96-wells 
plate using TaqMan PreAmp Master Mix Kit (Life Technologies, Carlsbad, CA) (Table 
5Table 6) with a specific reaction mix for each of the two human miRNA pools. The 
reaction mix included: 20 µl of TaqMan PreAmp Master Mix 2X, 8.5 µl of Nuclease-free 
Water and 4 µl of Megaplex PreAmp Primers Pool A/Pool B 10X. Subsequently, 7.5 µl of 
previously RT miRNA were added to the pre-amplification reaction mix. Pre-amplification 
thermal conditions consisted in an activation cycle 95° C for 10 min, 55°C 2 min, 72°C for 
2 min, 16 cycles of 95°C for 15 s and 60°C for 4 min, 99.9°C for 10 min to inactivate 
polymerases and final stage at 4°C. 
Subsequently, each pre-amplification product is diluted 1:20 with Nuclease-free Water, 
transferred in 8 wells of a 384-wells plate and mixed with TaqMan Open Array Real Time 
PCR Master Mix in ratio volume 1:1=MasterMix:cDNA with robot MicroLab STAR Let 
(Hamilton Robotics, Birmingham, UK).  
Open Array Reaction Mix was transferred from the 384-wells plate to a TaqMan Open 
Array MiRNA Panel with AccuFill System. Each panel was composed of a hydrophobic 
surface divided in 48 subarrays with 64 hydrophilic through-holes each (Figure 11). 
Generally, 16 subarrays cover the detection of the assays obtained by reverse 
transcription with Megaplex RT Primers Pool A v2.1 and Pool B v3.0. By reverse 
transcription of 756 miRNAs assays, based on Sanger miRBase v14 for human miRNAs, it 
is possible to screen the more well-studied miRNAs in 3 different subjects. In addition, the 
QuantStudio 12 K Flex Open Array manages to run and analyze up to 4 Open Array Panels 
at the same time.  
 54 
 
  
 
Reagents PreAmp Reaction Mix Volume per sample 
Megaplex PreAmp Primers Pool A/B 10X 4.0 µl 
TaqMan PreAmp Master Mix 2X 20.0µl 
Nuclease-free Water 8.5 µl 
Volume Reagents 32.5 µl 
RT miRNA sample  7.5 µl 
Total Volume 40.0 µl 
Table 5 PreAmp Reaction Mix. 
 
Stage Temperature Time 
Hold 95° C 10 min 
Hold 55° C 2 min 
Hold 72° C 2 min 
16 Cycles 
95° C 15 sec 
60° C 4 min 
Hold 99.9° C 10 min 
Hold 4° c ∞ 
Table 6 PreAmp PCR conditions. 
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Figure 11 Open Array Plate. Subarray partition and Through-Holes. 
Table 7 RT qPCR thermal cycles conditions.  
 
Step 
Enzyme 
Activation 
PCR 
Hold 
35 Cycles 
Denature Anneal Extend 
Temperature 95° C 95° C 30-60° C 65-70° C 
Time 10 min 15 sec 60 sec 
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Real-Time qPCR is a method based on PCR amplification to simultaneously quantify of 
samples of DNA or cDNA. Measure of the quantity for a specific target is measured by the 
fluorescence generated during PCR reaction. Fluorescence might be caused by different 
chemistry reaction. In these experiments, hybridization of specific probe was used to target 
cDNA. TaqMan probes are one of the methods with a more higher rate of fidelity and 
accuracy, as the TaqMan probes are designed to anneal only to unique target sequence. 
A typical Real-Time qPCR cycle is similar to a normal PCR consisting of two main 
steps as reported in Table 7. 
Real-Time PCR is a quantitative method, because data are recorded during exponential 
growth phase, when quantity of the reaction product is directly proportional to the quantity 
of the starting nucleic acid.  
miRNA quantification is based on fluorescence detected at every reaction cycle. During 
each cycle cDNA molecules are doubled since they reach a plateau when all the reagents 
are depleted and enzymes activity is drastically reduced.  
 Once the reaction is completed, Open Array software gives data for the further 
analysis. Useful data for analysis must fulfil two main characteristics: 
1. Relative Threshold Cycle (Crt): this value represents cycles number of PCR in which 
reaction efficiency of qPCR is in the beginning of the exponential phase, then the 
target miRNA is copied at the maximum speed. This data determines the starting 
quantity of the target miRNA. Briefly, higher Crts correspond to a low presence of the 
target miRNA, since that miRNA needs an high number of cycles to enter in its 
exponential phase and to give a signal detectable by the software. On the other hand a 
low Crt represents a high amount of starting miRNA. The software keeps trace of Crt 
from 1 to 35, but a good Crt number falls between the 10th and the 28th cycles. Earlier 
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than the 10th, the signal might be confused with background noise, then miRNAs, 
which have lower Crt, are considered undetermined. Crts higher than 28 are considered 
as undetermined too, because the exponential phase doesn't reach the plateau phase, so 
we aren't able to assess the beginning of the exponential phase. 
2. AmpScore: this value is calculated automatically by the software and gives a valuation 
of amplification efficiency and of the exponential curve. By default a good AmpScore 
has to be higher than 1.24, but it might be decreased to 1.1 if the visualized curve is 
checked by the operator and it is considered as good as a reference curve with 
AmpScore of 1.24. For this reason AmpScore values can be used to discriminate 
between false positives and negatives.  
 
Figure 12 Crt diagram. 
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Figure 13 Open Array workflow: from Purified miRNAs to Data Analysis. 
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3.7. VALIDATION BY RT-QPCR  
Validation of previous findings in plasma was performed by using Custom TaqMan 
Low Density Array on which the following TaqMan miRNA assays were pre-plated in 
triplicate: hsa-miR-151a-5p, hsa-miR- 107, hsa-let-7e-5p, hsa-miR-664a-3p, hsa-miR-210-
3p, hsa-miR-101-3p, hsa-miR-320b, hsa-miR-93-3p, hsa- miR-92a-3p, hsa-let-7c-5p, hsa- 
miR-378a-3p, hsa- miR-375, and the exogenous spike-in ath-miR159a for normalization. 
Validation of previous findings in EBC was performed by using Single TaqMan Low 
Density Array on a 384-wells plate in triplicates for the following miRNAs: hsa-miR-30a-
5p, hsa-miR-520b, hsa-miR-646, hsa-miR-378a-3p, hsa-miR-206, hsa-miR-9-5p, and the 
exogenous spike-in ath-miR-159a for normalization.  
3 μL of miRNAs (110 ng) for both plasma and EBC samples were reverse transcribed 
using Custom RT primer Pool (provided with Custom TL DA). The RT reaction mix of 12 
μl included: 6 μl Custom RT primer Pool, 0.3 μl dNTPs (100 nM), 3 μl MultiScribe 
Reverse Transcriptase (50 U/μl), 1.5 μl RT Buffer (10×), 0.19 μl RNase inhibitor (20 U/μl) 
and 1.01 μl nuclease-free water. After incubation on ice for 5 min reverse transcription was 
performed using a C1000 Thermal Cycler (Biorad, Hercules, CA). Thermal cycler 
conditions were as follows: one step of 16°C for 30 minutes, one step of 42°C for 30 
minutes, followed by 1 step of 85°C for 5 minute. The RT reaction was stored at -20°C. 
All reactions were performed as specified in the protocols of the manufacturer, described 
in the previous paragraph.  
3.8. DATA NORMALIZATION 
Crt not detected, with values over 28, or with an AmpScore <1.1 were considered not 
expressed and then deleted from the statistical analysis. Detected Crt values between 10 
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and 28 with an AmpScore ≥1.1 were considered well amplified and then normalized. 
Commonly, normalization is made in combination or with one of the two following 
methods. (a) The average Crt value obtained from all detected miRNA assays is used to 
normalize each singular miRNA assay. This strategy required a sufficient large amount of 
miRNA expressed among the entire study population or at least in a large majority of the 
subjects. (b) Reference endogenous miRNAs could be used to normalize other miRNA 
assays. The endogenous approach assumes that a reference miRNA is found stable in its 
expression among all the study subjects and it isn’t affected by any change in the 
organism. Often a change might affect expression in the expression of the chosen 
endogenous, then to avoid important data loss more than one endogenous is taken and 
normalization is made with the average value obtained by the chosen references. Unlike 
endogenous housekeeping genes, a specific miRNA rarely show to function as a good 
housekeeping among different tissues, then usually each tissue has its own endogenous 
miRNA that cannot function as well in other tissues. In addition, our study is focused on 
two biological matrices, blood and EBC that collect miRNAs from other districts. In facts, 
these two can be thought as basins inflow (blood like a more unspecified basin, while EBC 
like a lung district specific basin) where different organs can pour their miRNAs. Because 
of their characteristics, it is very hard to find and use one or more endogenous miRNA, as 
for other tissues.  
A new strategy for quantifying extracellular miRNAs in serum [111] has been proposed to 
normalize RT-qPCR miRNAs data to an external RNA spike-in control as it has been 
shown that the total RNA and total miRNA content of serum is an experimental variable 
and that normalization to candidate endogenous control miRNAs introduces a systematic 
bias in miRNA quantification. We used as external spike-in control, introduced during 
miRNA purification at the lysis phase with QIAzol, a miRNA from Arabidopsis thaliana 
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(ath-miR-159a), as it has no mammalian homologue. In addition to the external spike-in 
normalization strategy, introduction of an exogenous miRNA has a double effect: a) to 
monitor the efficiency of miRNA purification and b) to highlight co-purification of PCR 
inhibitors. 
Once data are acquired, all the 8 ath-miR-159a replicates in each Open Array Panel Pool A 
and B were taken together and the obtained average was used to normalize all the target 
miRNAs. As discussed before, ath-miR159a showed to remain constant between samples 
and Open Array run, for this it can be taken as a good reference miRNA, to which other 
target miRNAs can be normalized. Briefly, normalization was done as the difference (ΔCrt) 
between a specific Crt miRNA assay of Pool A and B and average Crt of the ath-Mir159a of 
the same Pool of the target miRNA, or Crt(target miRNA) – Crt(average ath-miR159a). 
When ΔCrt of a single miRNA assay is greater than 0, it means that the Crt of that specific 
miRNA is higher than the ath-miR-159a average Crt and its relative quantification is lower 
than the reference. While, when ΔCrt is minor than 0, the target miRNA Crt is lower than 
the spike-in ath-miR159a Crt and its relative quantification is higher than the reference. 
3.9. STATISTICAL ANALYSIS 
Once the ΔCrt was obtained, the Relative quantification (RQ) was calculated as 2-ΔCrt. 
Relative quantification gives information about how much a specific miRNA is up- or 
down-regulated in a specific group in order to calculate differences between case group 
and control group. 
We performed linear regression model adjusted for age, sex, BMI and smoking habits, to 
analyze possible expression differences between groups, i.e. MPM subjects vs PEA group, 
MPM subjects vs NM group. In order to fulfil the assumption of normality of the linear 
regression model RQ values were previously log2-transformed. 
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 We assumed that a p-value lower than 0.05 was a good marker to identify those 
miRNAs that showed a change in their expression between different healthy state.  
Due to the high number of dependent variable (miRNAs) simultaneously evaluated 
through separated linear regression models, False Discovery Rate (FDR) was applied to 
identify the potential top miRNAs. The FDR correction is designed to control the expected 
proportion of incorrectly rejected null hypotheses and used in multiple-hypothesis testing 
to reduce Type-1 errors A FDR p-value significance threshold of 0.10 was adopted to 
select significant top miRNAs. 
 
To categorize the MPM, PEA and NM subjects according to their expression patterns, 
hierarchical clustering analysis was performed using miRNA expressions with FC higher 
then 2 and p-value for median comparisons lower than 0.05.  
Qlucore software was used for cluster analysis and heat map chart construction for 
expression profile visualization.  
The heat map is a graphical representation of data using colors to indicate the level of 
espression: red colors indicate down-regulation while green colors indicate up-regulation 
of miRNA expression. 
Volcano plots were obtained to graphically compare the size of the fold change to the 
statistical significance level of each miRNA in group comparisons (MPM vs NM and 
MPM vs PEA). 
Briefly, every dots coincide with miRNAs found expressed by Open Array analysis, 
intercepts of every miRNAs on X and Y-axis determine the value of Fold Change (FC) and 
p-value, respectively. FC was calculated as the ratio between Relative Quantification (RQ) 
for a given miRNA of MPM group and that of the control group taken in account for the 
comparison. Hence, when FC was higher than 2, it corresponds to 2-folds up-regulation of 
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the miRNA in MPM group; while an FC value comprised between 0 and 0.5 reflects a 
down-regulation of 2-folds or more for the given miRNA. Values of FC are log2-
transformed, hence all the dots at left and right of the drawn vertical lines (intercepting X-
axis in ±1) are considered 2-folds negative or positive deregulated, respectively, in MPM 
subjects in respect of the considered control group. The Y-axis shows negative log10-
transformed p-values, hence lower and higher horizontal lines determine values of 0.05 
and 0.01, respectively, and all the miRNAs found over those lines are considered 
significantly differentially expressed in the MPM group in respect of controls group. 
 
We performed ROC curve analysis to evaluate the diagnostic ability of the validated 
miRNAs found in EBC and plasma. In a ROC curve each point represents a 
sensitivity/specificity pair corresponding to a particular decision threshold of RQ value. 
The area under the ROC curve (AUC) is a measure of how well the RQ threshold can 
distinguish between affected and healthy subjects. A miRNA that discriminate perfectly 
has a ROC curve that passes through the upper left corner (100% sensitivity, 100% 
specificity). Therefore the closer the ROC curve is to the upper left corner, the higher the 
overall accuracy of the miRNA. 
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4. RESULTS 
4.1. STUDY POPULATION 
The study population includes :  
I. 23 Malignant Pleural Mesothelioma (MPM) cases diagnosed according to the 
standardized criteria described in section 3.1.1; 
II. 19 subjects with Past Exposure to Asbestos (PEA) participating to an health 
surveillance program due to their past occupational exposure to asbestos; 
III. 9 Non-Mesothelioma (NM) cases hospitalized for pleural effusion but with 
negative VATS and immunohistochemical analyses for MPM . 
The main characteristics of the study subjects are reported Table 8.   
Most subjects in each group were males (73.9% in MPM , 78.9% in PEA and 88.9% in 
NM). BMI, age and smoking distributions did not differ across groups (p=0,81; p=0,2; 
p=0.82 respectively).  
Table 9 reports specific characteristics of each MPM, in particular the histological 
distribution and the main variables related to asbestos exposure such as occupation, period 
of exposure, latency (years since the beginning of exposure to diagnosis) and years since 
last exposure to EBC and Blood collection. The more frequent histological types were 
epithelioid (10 cases) and biphasic (11 cases). 12 cases had certain occupational exposure 
to asbestos; asbestos exposure was coded as possible in only 1 case with potential exposure 
due to job as safety system installer in explosion-risk plants. The median latency period 
was 57 years, and the time since last exposure and test collection ranged between 0 and 62 
years. 
15 out of 19 subjects with PEA were males (Table 10). These subjects underwent a 
surveillance program because included in an ad hoc registry by the Local Health Unit 
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(LHU) of their residence. A qualitative judgment about exposure as evaluated by the LHU 
was available for 17 subjects. 3 were considered at high exposure whereas the remaining 
subjects had low exposure. 11 PEA subjects had performed Broncoalveolar Lavage (BAL) 
to verify and quantify possible presence of asbestos bodies (AB): 2 were negative, for the 
others the number ranged between 1,6/ml and 18/ml. Interestingly, the highest asbestos 
burden was seen in two females who worked in cured meat packaging . 16 subjects had 
pleural plaques (a well-known indicator of past exposure to asbestos) at chest x-ray. In 
addition, two subjects had a radiological diagnosis of asbestosis (the number of AB in 
BAL was 10 and 6 respectively). The median duration of exposure was 27 years, and the 
time since last exposure and test collection ranged between 6 and 53 years.. 
The main characteristic of 9 NM cases are reported in Table 11. A possible exposure to 
asbestos was detected in 4 of them. 7 had a diagnosis of cancer ( 4 lung, 1 lymphoma, 1 
kidney, 1 breast).  
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Table 8 Main characteristic of the three study groups. 
Variable 
Malignant Pleural 
Mesothelioma 
Past Asbestos 
Exposed 
Non-
Mesothelioma 
Sex, n (%) M F M F M F 
  17 (73.9) 6 (26.1) 15 (78.9) 4 (21.1) 7 (88.9) 2 (11.1) 
Age, average (SD) [years]
a
             
  70.2 (7.8) 66.5 (6.4) 72.3 (7.4) 
Body Mass Index, average (SD)             
  25.1 (4.4) 26.3 (4.2) 26.7 (6.7) 
Smoking, n (%)             
Current - - - 
Never 6 (26.1) 9 (47.4) 2 (22.2) 
Former 12 (52.1) 7 (36.8) 5 (55.6) 
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Table 9 Main characteristics of Malignant Pleural Mesothelioma cases.  
ID Sex Date of Birth Age
a BMI Smoking
Asbestos 
Exposure
b Histology Occupation
Period of 
Exposure
Date of 
Diagnosis
Duration of 
Exposure
Latency 
(Years)
Years since 
Last Exposure
MPM01 M 04/10/1950 62 31 Former UN Epithelioid - - 26/11/2012 - - -
MPM02 M 26/03/1956 57 24 Current PO Biphasic
Safety System Installer in 
Explosion-Risk Plants 
1980 - 2012 30/11/2012 32 32 0
MPM03 M 28/07/1944 68 30 Former CO Epithelioid Car Maintenance Technician 1976 - 2002 13/12/2012 26 36 10
MPM04 M 22/06/1942 70 35 Former UN Biphasic - - 17/12/2012 - - -
MPM05 F 30/03/1954 59 21 Never UN Biphasic - - 20/12/2012 - - -
MPM06 M 23/11/1934 78 23 Former CO+EO Sarcomatoid
Security Service in Asbestos-
Caulked Plants
1949 - 1988 21/12/2012 39 63 24
MPM07 M 15/01/1940 73 22 Never UN Biphasic - - 04/02/2013 - - -
MPM08 M 13/12/1936 76 34 Former CO Epithelioid
Asbestos-Panels Retailer, 
Inventory
1980 - 1997 06/02/2013 17 33 16
MPM09 F 23/07/1958 55 18 Former UN Epithelioid - - 14/02/2013 - - -
MPM10 M 08/05/1940 73 22 Former CO Epithelioid Jewel Maker, Abestos-Panel User 1956 - 1986 22/02/2013 30 57 27
MPM11 F 09/02/1941 72 19 Current CO Epithelioid
Textile Industry, Laundry Worker, 
Seamstress
1960 - 1967 12/03/2013 7 53 46
MPM12 M 19/09/1936 77 25 Former CO Biphasic
Asbestos Brake Lining Repairing 
Service
1951 - 1992 04/04/2013 41 62 21
MPM13 M 28/07/1931 82 25 Former CO Biphasic Asbestos-Products Reseller 1946 - 1951 02/07/2013 5 67 62
MPM14 F 23/02/1955 58 22 Never UN Biphasic - - 09/07/2013 - - -
Asbestos Brake Lining Production 1953 - 1954 1
Electric Oven Operator in Metal 
Industry
1964 - 1989 25
MPM16 F 26/07/1937 76 21 Never CO Biphasic
Medal Maker, Asbestos-Panel 
User
1952 - 1958 29/07/2013 6 61 55
MPM17 M 07/09/1942 71 23 Current CO+EO Epithelioid Jewel Maker, Abestos-Panel User 1956 - 2003 22/08/2013 47 57 10
MPM18 M 21/02/1937 77 25 Never ENV Epithelioid - 1955 - 1956 14/11/2013 1 58 57
MPM19 F 22/09/1938 75 30 Never UN Epithelioid - - 10/12/2013 - - -
MPM20 M 03/02/1951 63 25 Current ENV+EO Biphasic - 1971 - 1972 26/02/2014 1 43 42
MPM21 M 28/02/1935 79 24 Former CO+EO Biphasic
Construction Industry Worker, 
Plumber, Cable and Tube Layer
1949 - 1969 13/03/2014 20 65 45
MPM22 M 03/04/1947 67 28 Current CO Biphasic
Construction Industry Worker, 
Plumber, Cable and Tube Layer
1963 - 2013 22/04/2014 50 51 1
MPM23 M 11/07/1944 70 25 Former UN - - - 08/05/2014 - - -
a) Age at diagnosis. 
b) Classification of Asbestos Exposure: CO, certain occupational; PO, probable occupational; EO, extra-occupational; ENV, environmental; and UN, unknown.
267522/09/1938MMPM15 Former 246018/07/2013EpithelioidCO
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Table 10 Main characteristics of subjects with Past Asbestos Exposure. 
 
ID Sex
Date of 
Birth
Age
a BMI Smoking
Asbestos 
Exposure
b Exp Level
c
BAL
d
Diagnosis
e Occupation
Period of 
Exposure
Date of 
Sampling
Duration of 
exposure
Years since 
Last Exposure
PEA01 F 23/03/1948 65 20 Former CO High - PP Gunny Sack Recycler 1961 - 1963 16/01/2013 2 50
PEA02 F 06/03/1946 67 26 Never CO High - PP Gunny Sack Recycler 1959 - 1960 16/01/2013 1 53
PEA03 M 08/06/1948 65 27 Never CO Low - PP
Construction Industry 
Bricklayer (Roofs)
1963 - 2007 18/01/2013 44 6
PEA04 M 16/04/1957 56 35 Current CO Low 0 PP, PE Glassworks 1980 - 2000 18/01/2013 20 13
PEA05 M 09/10/1945 67 28 Never CO Low 10 PP, Asb Caulker 1973 - 1992 22/01/2013 19 21
PEA06 M 04/11/1945 67 28 Never CO Low - Neg
Welder Balcksmith in 
Metal Industry
1971 - 1998 24/01/2013 27 15
PEA07 M 01/09/1932 80 22 Former CO Low 7 PP
Upholsterer - Fireproof 
Furniture Production 
Maker
1948 - 1997 19/01/2013 49 16
PEA08 M 06/06/1937 76 26 Current CO Low 2 PP
Boiler Maintenance 
Technician 
1973 - 1999 30/01/2013 26 14
PEA09 M 30/09/1940 72 27 Never CO High 6 PP, Asb Caulker 1963 - 1998 01/02/2013 35 15
PEA10 M 12/05/1949 64 24 Former CO Low 2 PP
Metalworker in Metal 
Industry
1970 - 2001 04/02/2013 31 12
PEA11 M 13/05/1949 64 24 Current CO Low 3 PP
Metalworker in Metal 
Industry
1973 - 2000 04/02/2013 27 13
PEA12 M 26/02/1946 67 27 Never CO Low 0.5 PP Caulker 1968 - 1995 05/02/2013 27 18
PEA13 M 06/11/1949 63 21 Former CO Low 1.6 PP
Welder Balcksmith in 
Metal Industry
1969 - 2001 12/02/2013 32 12
PEA14 M 18/12/1954 58 26 Former CO Low - Neg
Welder Balcksmith in 
Metal Industry
1970 - 1991 28/03/2013 21 22
PEA15 M 30/05/1947 66 30 Former CO Low - Neg
Welder Balcksmith in 
Metal Industry
1971 - 1996 05/03/2013 25 17
PEA16 F 25/08/1950 63 20 Never CO Low 18 PP Cured Meat Factory 1965 - 1987 17/04/2013 22 26
PEA17 F 03/06/1956 57 35 Never CO Low 13 PP Cured Meat Factory 1971 - 2001 17/04/2013 30 12
PEA19 M 08/03/1940 74 25 Former CO - - PP Electrician 1954 - 1998 25/03/2014 44 16
PEA20 M 03/04/1941 73 26 Never CO - - PP
Rubber Vulcanization 
Technician
1968 - 1984 01/03/2014 16 30
a) Age at samples taking
b) Classification of Asbestos Exposure: CO, certain occupational.
c) Qualitative Exposure Level to asbestos evaluated by LHO.
d) Number of AB per ml are reported.
e) Diagnosis PP, pleural plaques; PE, pleural effusions; Asb asbestosis; and Neg, negative.
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ID Sex Date of Birth Age
a BMI Smoking
Asbestos 
Exposure
b Diagnosis Occupation
Date of 
Diagnosis
NM01 F 09/08/1953 59 20 Former UN Lung Cancer - 14/11/2012
NM02 M 29/06/1933 79 24 Former UN Inflammatory Status - 27/11/2012
NM03 M 23/02/1933 80 26 Never PO Kindey Cancer
Power Plant, Occasionally 
Switchboard Wirer
08/05/2013
NM04 M 15/01/1948 66 41 Never UN Lung Cancer - 23/07/2013
NM05 M 10/09/1943 70 21 Former PO Lymphoma
Short Time Periods in Asbestos-
Caulked Plants
21/08/2013
NM06 M 24/02/1932 82 27 Former UN Lung Cancer - 08/11/2013
NM07 M 12/05/1940 74 34 Former PO
Silicosis, Bilateral 
Pleural Thickening
Marble Cutter, Short Exposure 
Periods To Serpentine
07/03/2014
NM08 M 07/11/1942 71 22 Current PO Lung Cancer Construction Industry Bricklayer 28/03/2014
NM09 F 03/09/1945 69 19 Current UN Breast Cancer - 10/04/2014
a) Age at diagnosis. 
b) Classification of Asbestos Exposure: PO, probable occupational; and UN, unknown.
Table 11 Main characteristics of Non-Mesothelioma subjects. 
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4.2. MIRNOME SCREENING WITH OPEN ARRAY 
We analyzed miRNA expression profiles in Exhaled Breath Condensate (EBC) and 
plasma, using Open Array high-throughput technology, that allows to investigate in high-
fidelity and short-time 733 well studied miRNAs spotted in single and divided in two pool 
A and B for both reverse-transcription and quantification. 
Since EBC and plasma don’t have any endogenous miRNAs which are able to function 
as normalizer, we used the average of the octuplicate Cts obtained from the external spike-
in ath-miR-159a. The usage of an external spike-in has been recently validate as 
normalizing method for microarrays data in absence of a well-known endogenous miRNA 
[111]. 
 To consider a miRNA as expressed, it has to fulfil two criteria after analysis with Open 
Array: 1) Cycle threshold (Ct) cannot be higher than the 28
th
 cycles; 2) AmpScore must be 
equal or higher to 1.1. Among the 733 analyzed miRNAs in EBC and plasma we found a 
total of 444 and 256 expressed miRNAs, respectively. In Table 12 are reported how many 
expressed miRNAs were found in each biological matrices across the three studied groups. 
 
Table 12 Numbers of expressed miRNAs in each group detected by Open Array analysis. 
Numbers of expressed miRNAs in each (%) 
  MM PEA NM 
EBC 157 (61.3) 215 (84.0) 113 (44.1) 
Plasma 369 (83.1) 401 (90.3) 335 (75.5) 
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4.3. HEAT MAP HIERARCHICAL CLUSTER ANALYSIS 
Expression profiles determined by Open Array analysis in 23 MPM, 19 PEA and 9 NM 
were used for Hierarchical Cluster Analysis utilizing Qlucore software. The Cluster 
Analysis is an explorative analysis that tries to identify structures within the data. More 
specifically, it tries to identify homogenous groups of cases, showing a similar expression 
of a specific microRNA pattern.  
Cluster analysis was performed on differential miRNAs defined as those miRNAs with 
FC higher than 2 or lower than 0.5 and p-value lower than 0.05 (using the Mann-Whitney 
U test). 
In Figure 14Figure 15, hierarchical cluster analyses are reported for expression profile 
from EBC and plasma, respectively. In both the figures MPM, PEA and NM groups are 
marked in yellow, blue and red, respectively. In EBC, 31 differential miRNAs were used 
to hierarchically cluster the three groups, while in plasma deregulated miRNAs were a 
total of 55. 
The EBC Heat map did not show any specific clustering of the samples. 
The plasma Heat map, on the contrary, showed an imperfect clustering. While most of 
the cancer-free samples clustered separately, some were dispersed within the group of the 
malignant samples. The separation may be due to a specific expression of miRNAs in 
benign diseases commonly present in PEA and MPM, e.g., asbestosis or pleural plaques.
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Figure 14 Heat map of differential miRNA expression in EBC of MPM and control 
groups. Cluster analysis was performed using miRNA expressions with statistical significance 
(p-value<0.05) and a FC<0.5 (red=down-regulation) or FC>2 ( Green=up-regulation). 
MPM samples are marked yellow, PEA blue , and NM red. 
 73 
 
Figure 15 Heat map of differential miRNA expression in plasma of MPM and control 
groups. Cluster analysis was performed using miRNA expressions with statistical 
significance (p-value<0.05) and a FC<0.5 (red=down-regulation) or FC>2-folds ( 
Green=up-regulation). MPM samples are marked yellow, PEA blue, and NM in red. 
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4.4. MIRNA ANALYSIS IN EXHALED BREATH 
CONDENSATE  
We analyzed the expression of 733 miRNAs in EBC obtained from three study groups. 
After quality control and filtering steps, we detected 157 miRNAs in MPM, 113 
miRNAs in NM and 215 miRNAs in PEA that were considered for subsequent analyses, 
ie. Multiple linear regression adjusted for gender, age, BMI, and smoking habits. 
When we compared MPM and PEA, we found 8 miRNAs having, on average, different 
expression between the two groups (p < 0.05); and all of them had false discovery rate 
correction (FDR) of < 0.1 (Appendix B - EBC). 
When we compared MPM and NM, we found 3 miRNAs having different expression 
between the two groups (p < 0.05); and again all of them had false discovery rate 
correction (FDR) of < 0.1 (Appendix B - EBC). 
In Figure 16, comparisons between MPM vs PEA (Figure 16 A) and MPM vs NM 
(Figure 16 B) are reported, using a volcano-plot. Briefly, every dots represents a specific 
miRNA: on X and Y-axis the value of Fold Change (FC) and p-value are reported. 
As shown in Figure 16 A among the 131 miRNAs that have passed criteria of Ct≤28 
and AmpScore>1.1, and were expressed in both MPM and PEA, only 7 showed p-value 
lower than 0.05 and a FC greater than 2-folds. Three of them (hsa-miR-30a-5p, hsa-miR-
141 and hsa-miR-518b) were down-regulated in MPM; while hsa-miR-520b, hsa-miR-646, 
hsa-miR-520c-3p and hsa-miR-888 were up-regulated in MPM group.  
Figure 16 B represents the Volcano plot obtained by the comparison between MPM and 
NM groups. hsa-miR-378a-3p, hsa-miR-206 and hsa-miR-9-5p resulted in a lower 
regulation in MPM than NM subjects. 
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Figure 16 Volcano plot for EBC screening. Every dots correspond to a specific miRNA. X-axis reports FC as Log2, then dots on the left and 
right of vertical lines are considered to be 2-folds, negatively and positively, deregulated in MPMs than the reference control group. 
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4.5. MIRNA ANALYSIS IN PLASMA 
Using a workflow similar to the one described for EBC analysis, in plasma we detected 
369 miRNAs in MPM, 401 miRNAs in NM and 335 miRNAs in PEA that were considered 
for subsequent analyses.  
Comparing MPM and PEA, we found 124 miRNAs which were differentially express 
between the two groups (p < 0.05); and 82 of them passed the false discovery rate 
correction (FDR) of < 0.1 (Appendix B - Plasma). 
Comparing MPM and NM, we found 39 miRNAs having different expression between the 
two groups (p < 0.05); and 1 of them passed the false discovery rate correction (FDR) of < 
0.1 (Appendix B - Plasma). 
As expected, in plasma we were able to detect an higher number of miRNAs compared 
to EBC, since plasma collects miRNAs coming virtually from all body districts, while 
EBC is only representative of pulmonary environment. 
Figure 17 A reports the comparison between MPM and PEA subjects. 115 out of 351 
miRNAs showed a p-value≤0.05 and FC>2-folds or FC <0.5.  
105 resulted to be significantly down-regulated in MPM compared to PEA subjects, 
whereas 9 miRNAs were upregulated in MPM subjects. 
The Volcano-plot comparing MPM and NM subjects is reported in Figure 17 B. 335 
miRNAs showed a p-value≤0.05 and FC>2-folds or FC <0.5. 
44 miRNAs were significantly down-regulated in MPM subjects compared to NM 
subjects. 
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Figure 17 Volcano plot for plasma screening. Every dots correspond to a specific miRNA. X-axis reports FC as Log2, then dots on the left 
and right of vertical lines are considered to be 2-folds, negatively and positively, deregulated in MPMs than the reference control group. 
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4.6. SELECTION OF CANDIDATE MIRNAS 
To validate candidate miRNAs as molecular biomarkers for malignant mesothelioma, we 
followed two main criteria:  
1. candidate miRNAs should show a strong statistical difference in expression in the 
compared groups,  
2. and be expressed in at least 50% of the examined subjects.  
When we consider EBC, hsa-miR-30a-5p, and hsa-miR-520b and hsa-miR-646 satisfied 
these two criteria in the comparison between MPM vs PEA and the same hold for hsa-
miR-378a-3p, hsa-miR-206 and hsa-miR-9-5p in the comparison between MPM vs NM. 
subjects, and hence were chosen as candidate biomarkers for malignant pleural 
mesothelioma diagnosis and used for further validation by RT-qPCR. 
Among the analyzed miRNAs only three passed the previous described criteria of FC and 
p-value.  
The 6 miRNAs chosen as candidate biomarkers for further validation by RT-qPCR are 
reported in Table 13 . 
 EBC MPM vs PEA MPM vs NM 
miRNA name pvalues FC Regulation pvalues FC Regulation 
hsa-miR-30a-5p 0.0590 0.28 ↓       
hsa-miR-520b 0.0147 3.83 ↑       
hsa-miR-646 0.0202 10.99 ↑       
hsa-miR-206       0.0312 0.11 ↓ 
hsa-miR-378a-3p       0.0148 0.05 ↓ 
hsa-miR-9-5p       0.0438 0.27 ↓ 
 
Table 13 List of candidate miRNAs in EBC. P-values<0.5 indicate statistical significance 
for the deregulation of given miRNA in MPM versus one of the reference control group. FC 
was calculated has the ratio between RQ for given miRNA in MPM and the same miRNA 
RQ in the reference control group. 
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In plasma, due to the high number of differentially expressed miRNAs, in addition to the 
above mentioned criteria, which allowed the selection of 4 candidate miRNAs (hsa-
miR151-5p, hsa-miR-93-3p, hsa-miR-190-5p and hsa-miR-642a-5p), we applied further 
criteria based on: 
1. being differentially expressed in both MPM vs PEA and MPM vs NM (hsa-let-7c-
5p, hsa-let-7e-5p, hsa-miR-101-3p, hsa-miR-320b, hsa-miR-375 and hsa-miR-92a-
3p) 
2. having a previously reported role in oncogenic and inflammatory processes (hsa-
miR-107, hsa-miR-210-3p and hsa-miR-664a-3p) 
Therefore, we selected a total of 13 miRNAs, reported in Table 14.  
 
 Plasma MPM vs PEA MPM vs NM 
miRNA name p-value FC Regulation p-value FC Regulation  
hsa-miR-151a-5p 0.0001 0.89 ↓       
hsa-miR-93-3p 0.0001 0.30 ↓       
hsa-miR-190a-5p       0.0036 0.31 ↓ 
hsa-miR-642a-5p       0.0050 0.24 ↓ 
hsa-let-7c-5p 0.0065 0.42 ↓ 0.0112 0.31 ↓ 
hsa-let-7e-5p 0.0029 0.45 ↓ 0.0557 0.41 ↓ 
hsa-miR-101-3p 0.0098 0.50 ↓ 0.0381 0.39 ↓ 
hsa-miR-320b 0.0057 0.51 ↓ 0.0182 0.37 ↓ 
hsa-miR-375 0.0151 0.36 ↓ 0.0014 0.16 ↓ 
hsa-miR-92a-3p 0.0452 0.65 ↓ 0.0403 0.37 ↓ 
hsa-miR-107 0.0178 0.42 ↓       
hsa-miR-210-3p 0.0263 0.29 ↓       
hsa-miR-664a-3p 0.0362 0.32 ↓       
 
Table 14 List of candidate miRNAs in Plasma. P-values<0.5 indicate statistical 
significance for the deregulation of given miRNA in MPM versus one of the reference 
control group. FC was calculated has the ratio between RQ for given miRNA in MPM and 
the same miRNA RQ in the reference control group. 
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4.7. VALIDATION OF MIRNAS IN REAL TIME PCR 
Using the previously reported criteria, quantitative real-time PCR was performed to 
validate OpenArray results on the selected miRNAs. 
Specifically, miRNAs chosen for validation test in EBC samples were analyzed by 
single assays run on 7900HT Fast Real-time PCR system. miRNAs chosen for validation 
test in plasma samples, were analyzed by Custom TaqMan Low Density Array run on 
7900HT Fast Real-Time PCR System. 
In EBC, miR-520b and miR-646 were not detectable. Among the remaining miRNAs 
(miR-30a-5p, miR-206, miR-378a-3p and miR-9-5p), only miR-30a-5p was validated and 
resulted to be significantly down-regulated in MPM patients compared to PEA (Table 15). 
The results pertaining validation in plasma are reported in Table 16: 3 (hsa-miR-151-5p, 
hsa-miR-107 and hsa-let-7e) out of 13 miRNA candidates were validate for their 
expression profiles in the comparison between MPM and PEA. 
  
EBC MPM vs PEA 
miRNA name p-values FC Regulation 
miR-30a-5p 0.0050 0.26 ↓ 
miR-9-5p 0.0986 0.60 ↓ 
miR-206 0.1241 0.55 ↓ 
miR-378a-5p 0.2625 0.54 ↓ 
 
 
 
 
 
Table 15 Results of miRNA validation in EBC. 
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4.8. ROC CURVE ANALYSIS 
To evaluate the accuracy in determining the diagnosis for malignant mesothelioma we 
performed ROC analysis for the validated miRNAs found in EBC and plasma in the 
comparison MPM vs PEA.  
For the only miRNA validated in EBC (hsa-miR-30a-5p) (Figure 18 A), we obtained an 
AUC value of 0.77 (95% CI 0.6223 - 0.9232, p-value<0.0005). The best Relative 
Quantification (RQ) cut-off used in the analysis was 0.0001, with a sensitivity of 82% and 
a specificity of 70%. 
Individual ROC analysis were first performed for the three miRNAs validated in 
plasma. Results are shown in figure XXX B, C and D. hsa-miR-151-5p showed an AUC 
value of 0.77 (95% CI 0.6333-0.9144, p-value<0.0001) (Figure 18 B). A proper cut off for 
hsa-miR-151-5p using a RQ value of 0.09 with a sensitivity of 83% and a specificity of 
70%. hsa-miR-107 and hsa-let-7e-5p revealed an AUC value of 0.75 (95%CI 0.6028–
0.9059, p-value<0.001) and 0.72 (95%CI 0.5697–0.8825, p-value<0.005), respectively 
Table 16 Results of miRNA validation in plasma. 
 Plasma MM vs PEA 
miRNA name p-values FC Regulation 
hsa-miR-151a-5p 0.0041 0.36 ↓ 
hsa-miR-107 0.0150 0.47 ↓ 
hsa-let-7e-5p 0.0252 0.45 ↓ 
hsa-miR-664a-3p 0.0828 0.52 ↓ 
hsa-miR-210-3p 0.1016 0.58 ↓ 
hsa-miR-320b 0.1465 0.59 ↓ 
hsa-miR-101-3p 0.1502 0.58 ↓ 
hsa-miR-93-3p 0.1564 0.62 ↓ 
hsa-miR-92a-3p 0.1658 0.69 ↓ 
hsa-let-7c-5p 0.4720 0.69 ↓ 
hsa-miR-378a-3p 0.6328 1.15 ↑ 
hsa-miR-375 0.8352 0.86 ↓ 
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(Figure 18 C and D). A proper cut off for hsa-miR-107 using a RQ value of 0.01 was 
determined to discriminate between MPM from PEA revealing a sensitivity of 65% and a 
specificity of 85%; while hsa-let-7e-5p cut off was calculated in a value of 0.14, and 
produces a sensitivity of 87% and a specificity of 60%. When we combined the three 
miRNAs, the AUC value was 0.79 (95%CI 0.65–0.92) with a sensitivity of 78% and a 
specificity of 70%. 
The last step was the calculation of a single ROC curve for the combined 4 validated 
miRNAs in EBC or plasma (Figure 18 E). The AUC found by this analysis was equal to 
0.85 (95% CI 0.72 – 0.97) with 86% sensibility and 80% specificity. 
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Figure 18 ROC curves of EBC hsa-
miR-30a-5p (A), and plasma hsa-miR-
151-5p (B), hsa-miR-107 (C), hsa-let-
7e-5p (D), and combined 4 miRNAs 
validated in EBC and Plasma analysis 
(E). ROC curves were generated using 
qPCR data of miRNA expression in 
samples of MPM versus PEA. Areas 
under the ROC curves (AUC), 95% 
CIs, and p-value are shown. 
 84 
 
5. DISCUSSION AND CONCLUSIONS 
Malignant Pleural Mesothelioma (MPM) is an aggressive cancer refractory to current 
therapies, the incidence of which is expected to rise in the next decades [1]. Recent 
projections have suggested that MPM mortality rates, estimated using mortality from 
primary pleural tumours, will continue to increase in the next 20 years in most European 
countries [2, 3]. 
MPM is often difficult to distinguish from lung adenocarcinomas and accurate diagnosis 
require multiple time-consuming tests (i.e. light microscopy with a panel of 
immunohistochemical stains, as gold standard [38]) as well as invasive procedures (i.e. 
thoracoscopy [112]). The lack of efficient tumor biomarkers for MPM diagnosis and 
medical survey plays a fundamental role for the development of a universally accepted 
therapeutic approach and a clearer understanding of the major molecular pathways of 
MPM is still needed to establish diagnostic and therapeutic methods.[74] 
With a median survival of less than 1 year and a 5-year survival rate of less than 5% 
[113], prognosis of MPM remains very poor [114]. 
In recent years, microRNA expression (for example detected in plasma) have been 
closely associated with several cancers, including lung diseases [115], as well as MPM 
[116]. However, only a few studies focused on the investigation of circulating miRNA 
expression in MPM with inconsistent findings. In addition, the extreme variability of 
applied techniques hampered , a reliable comparison among studies .  
 The possibility of measuring miRNA expression in EBC of MPM cases has never been 
evaluated. 
miRNAs measured in plasma and EBC might give different information, although 
complementary. Plasma collects circulating miRNAs coming from all the different body 
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districts and, thus, plasma miRNAs are more a systemic marker. On the contrary, EBC is 
representative of the pulmonary environment only, and might be much more tissue 
specific. 
We have performed a screening of 733 miRNAs by high-throughput Open Array 
analysis in MPM affected-patients and two different control groups; one formed by healthy 
subjects with a Past Asbestos Exposure (PEA), and the other composed by subjects 
enrolled among patients with pleural effusions due to other causes (NM). For each subject 
we analyzed paired samples of miRNAs purified from plasma and EBC. 
The comparison between MPM and PEA allowed us to evaluate miRNA expression 
between diseased and healthy subjects, while the comparison between MPM and NM 
subjects has been chosen to investigate the ability of differential miRNAs to discriminate 
between MPM and other pulmonary diseases.  
After Real Time validation, we identified one miRNA in EBC (hsa-miR-30a-5p) and 
three miRNAs in plasma (hsa-miR-151-5p, hsa-miR-107, and hsa-let-7e-5p), able to 
discriminate between MPM and PEA subjects. The combination of the 4 miRNAs gives 
even a better score, with a ROC curve which shows an AUC = 0.85. To our knowledge this 
is the first study in MPM which investigate miRNA expression in EBC and identify a 4-
miRNA signature which might be useful for MPM diagnosis.  
In the comparison between MPM and NM, we were not able to validate any miRNAs. 
This may be due the small sample size and to a non-homogeneous composition of the NM 
group, being composed by 7 subjects affected by different cancers, 1 subject with silicosis 
and 1 subject presenting an inflammatory status.  
 
Previous studies have suggested a possible role for miRNA deregulation in MPM. 
There have been some reports on the role of miR-30 family members that may be related 
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to the pathogenesis of tumors [117]. Mitochondrial fission is involved in the initiation of 
apoptosis, while apoptosis is relevant to the tumorigenesis. Li et al. reported that the 
overexpression of miR-30 family members, including miR-30a, miR-30b and miR-30d, 
was able to reduce mitochondrial fission initiated apoptosis by targeting p53, which is 
transcriptionally activated by the mitochondrial fission protein, dynamin-related protein-1 
(Drp1) [118]. Cell senescence is a major tumor suppressing mechanism. Martinez et al. 
demonstrated that miR-29 and miR-30 regulate B-Myb expression by binding to its 3’UTR 
and suggested that these microRNAs play an important role in Rb-driven cellular 
senescence [119]. It has also been demonstrated the down-regulation of miR-30a in 
chronic lymphocytic leukemia (CLL) [120], lung cancer [121], colon cancer [122], 
supporting the oncogenic role of miR-30a-5p, which we found down regulated in EBC of 
MPM patients.  
In MPM, we found miR-151-5p significantly down-regulated. In accordance with this 
observation, lower expression of circulating miR-151-5p miRNA expression was observed 
in the malignant pleural effusion (MPE) in non-small-cell lung cancer (NSCLC), and was 
associated with poor survival [123]. 
We also observed a down regulation of miR-107 in MPM, according to the previous 
reported data showing that miR-107 induces cell cycle G1 arrest and inhibits invasion by 
targeting cyclin dependent kinase 6 (CDK6), thereby inhibiting tumor progression in 
gastric cancer, pancreatic cancer, and NSCLC cell lines [124-126]. 
Let-7 has a highly conserved sequence across organisms from C.elegans to humans. It 
regulates the expression of a range of genes through its 5′ seed sequence (5′-UGAGGUA-
3′), which binds to corresponding sequences located in the 3′ UTRs of genes. Notably, the 
loss of let-7 expression is often considered to have prognostic value since it indicates poor 
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survival in many cancers [127]. In agreement with this data, we observed a down-
regulation of let-7e-5p in MPM. 
 
The novel use of EBC is interesting, but at the same time challenging: the amount of 
miRNAs present in this biospecimen is extremely low and limit our capability of detecting 
them. To overcome this technical issue, one possibility would be to collect at least two 
samples for each subject, trying to maximize miRNA yield. 
The main limitation of this study is the limited number of subjects, especially for the NM 
group. In future investigations, it will be fundamental to increase the number of subjects 
and, for the NM group, to select subjects on the base of a more homogeneous health status. 
A second limitation is that the use of endogenous controls to normalize circulating target 
miRNAs is very controversial. Thus far a real endogenous control for serum-based miRNA 
detection has not well established. Previous studies reported that the use of a single internal 
gene for normalization leads to relatively large error; thus, using multiple reference genes 
may be a better strategy to evaluate target gene expression [128, 129]. In this study, 
however, it was difficult to apply this strategy, since in EBC the subset of miRNAs 
expressed by each subject was extremely variable, and the miRNAs expressed by all 
subjects were too low. Frequently used reference genes, such as U6 and 5S ribosomal 
RNA, were found a less-stable expression than others or degraded in serum sample [104]. 
For these reasons, we decided to use an exogenous non-human spike-in control, which was 
added to each samples and quantified [130].  
 
In conclusion, data obtained in this project, support a possible role of miRNAs in the 
etiology of malignant pleural mesothelioma but need confirmation in larger samples.  
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APPENDIX A 
QUESTIONARIO SULLA STORIA DI LAVORO 
E SULLE ABITUDINI DI VITA 
Centro Operativo Lombardia 
_______________________________________________________________________________________
Tutte le domande si riferiscono a: 
Cognome …………………………………………………………………..….……………… N. 
identificazione 
Nome …….…….………………….……………………………………..…………………… |__|__|__|__|__| 
Data di nascita |__|__| / |__|__| / |__|__|__|__| Sesso: |_| M |_| F 
Luogo di nascita ……………………………………………………..……..…………… Provincia 
……………..…….. 
Ultimo domicilio (dove abita): Via 
.........………......………………………………………..................…………..…...... 
Comune ........................………………………………....………… Provincia .………………... C.A.P. 
|__|__|__|__|__| 
Telefono 
……………………………….....………………………………………..……………………………………... 
- Se il domicilio è differente dalla residenza, specificare anche la residenza: 
Ultima residenza (indirizzo): Via ........……….........…...................……………………………………………. 
Comune ........................……………………….………… Provincia .………………... C.A.P. |__|__|__|__|__| 
Telefono …………………………..……………………….....…………………………………………... 
Stato civile ..........…………………………………….…..................…..... Se sposato, anno di matrimonio 
|__|__|__|__| 
Titolo di studio (o ultima classe frequentata): 
...........................…………………………………….................................................……..…………………… 
_______________________________________________________________________________________ 
Data intervista |__|__| / |__|__| / |__|__|__|__| 
Orario INIZIO intervista |__|__|,|__|__| - Orario FINE intervista |__|__|,|__|__| 
Luogo dell'intervista 
…………………………………………………………..………………………...………….……. 
Intervistatore (nome e 
qualifica)...………….……………………………………………..……………………………… 
Ente .…………………………………………………………………………………..………………………. 
Recapito telefonico intervistatore ……………………………………………………………………………... 
PARTE PRELIMINARE: Fattori di confondimento sul livello di mi-RNA 
Peso: ……………..Kg 
Altezza …………….cm. BMI …………….. 
1. È attualmente fumatore? SI NO 
- se ‘SI’, da quanti anni fuma? …………….. 
- quante sigarette fuma in una giornata? …………….. 
- quante sigarette ha fumato oggi? …………….. 
2. Soffre di qualche malattia cronica? SI NO 
- se ‘SI’, quale? …………………………………………………………  
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3. Le sono mai stati diagnosticati enfisema polmonare/bronchite cronica?  
 SI In quale anno? ………………………...... 
 NO 
4. Attualmente è in terapia con cortisone o farmaci antinfiammatori?  
 SI (indicare i nomi dei farmaci) ……………..…………………………...... 
 NO  
- se ‘SI’, per quale motivo? …………..……………..…………….………….. 
 …………..……………..…………….…………………………………………… 
- ha assunto la terapia oggi? SI ……………...…..…………….………….. 
NO  
 
5. Abitualmente assume altri farmaci? 
SI (indicare i nomi dei farmaci) ……………..…………………………...... 
NO     ……………..…………………………...... 
6. Ha mai sofferto di rinite o asma allergico? SI NO 
- se ‘SI’, sa indicare a quali allergeni è sensibilizzato?  
 …...………………………………………………………………………………... 
- ha avuto disturbi su base allergica nell’ultima settimana? SI NO 
 …...………………………………………………………………………………... 
 
7. Soffre di reflusso gastroesofageo, ernia jatale, o in generale di disturbi della digestione? 
 SI …………...…..…………….……………………………… 
 NO  
 
8. Nell’ultima settimana ha sofferto di uno dei seguenti disturbi? 
- gengivite o aftosi del cavo orale 
- ascesso o granuloma dentale 
- epistassi (sangue dal naso) 
- rinite / croste dolorose nel naso 
- mal di gola / tonsillite / infezioni delle vie aeree 
 
9. Utilizza protesi dentarie? SI NO 
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PARTE A: ABITUDINI AL FUMO 
_______________________________________________________________________________________ 
 
Al. Fuma?   |_| SI  
|_| NO 
|_| HA SMESSO 
|_| NON SO 
 
A2. Se è o è stato fumatore, cosa fuma/fumava? 
|_| Sigarette   |_| con filtro  
|_| senza filtro 
|_| parte con, parte senza 
|_| non so 
|_| Sigari 
|_| Pipa 
|_| Non so 
 
A3. A che età ha cominciato a fumare? ……………………………………………………...…………..… |_| 
NON SO 
 A che età ha smesso? ……...………………………………………………………………...………… |_| 
NON SO 
 
A4. Quante sigarette fuma/fumava al giorno? …………………………………………………...………… |_| 
NON SO 
 
_______________________________________________________________________________________ 
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PARTE B: STORIA PROFESSIONALE - PARTE GENERALE 
______________________________________________________________________________________________________________________________________
______ 
(In base alle risposte, integrare con le schede generiche previste e, per attività di tipo industriale o artigianale, anche con eventuali schede specifiche) 
 
B1. Svolge attualmente un'attività professionale?   |_| SI  |_| NO 
Se no, indicare il motivo: 
……………..………………………………………………..…………………………..……………………………………………............…………. 
 
B2. Storia professionale completa. 
 
 
N. 
Inizio Fine 
 
Nome, attività dell'Azienda, Città 
 
Mansione 
Età Anno Età Anno   
     
 
 
       
       
       
       
 
 
 
 
N. 
Inizio Fine 
 
Nome, attività dell'Azienda, Città 
 
Mansione 
Età Anno Età Anno   
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N.B.: in caso di lavoro discontinuo o saltuario specificare la durata complessiva (< 6 mesi o 1 volta alla settimana). 
 
 E’ eventualmente disponibile il libretto di lavoro?  |_| SI  |_| NO  |_| NON SO 
 
B3. Svolge o ha mai svolto lavori saltuari?    |_| SI  |_| NO 
 Se si, li descriva nella storia professionale completa……………………………………………………………………………………………………………………….. 
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B4. SERVIZIO MILITARE 
_____________________________________________________________________________________________
_______ 
 
- Ha fatto il militare?          |_| SI  
 |_| NO 
 Se NO, specificare il motivo dell'esonero: 
……………………………………………………………………………………... 
 
…………………………………………………………………………………………………………………………
………... 
 
…………………………………………………………………………………………………………………………
………... 
 Se SI, quando? Dal ………….. al ……...….. Di leva |_| Di carriera |_|  
 In tempo di guerra?         |_| SI  
 |_| NO 
- In quale arma ha fatto il servizio militare? 
...................………………………....................................……………………….……………………...………………
……….. 
Dove? ………………………………………..…...……………..….. Dal ………….…..…… al 
.……………...…..… 
Con quali mansioni? 
...............................……………..……………………………………………...………………… 
- Durante il servizio militare ha mai lavorato alla riparazione di mezzi meccanici?  |_| SI  |_| NO 
Se si, specificare il tipo di mezzo e di 
intervento:…………………………………….…………………….……………………. 
………………………………………………...………………………………..……………………….………...……
………… 
- Ha mai guidato carri armati o mezzi blindati?      |_| SI   |_| NO 
Se si, si ricorda con cosa erano coibentati: 
……………………………………….………………………………….…….……. 
………………………………………………...…………………………………...……………………………………
………... 
- Ha mai fatto parte di squadre antincendio?       |_| SI   |_| NO 
 Se si specificare sa ha fatto uso di materiali in amianto o contenenti amianto (tute, guanti, etc.): 
…………………………….. 
…...….………………………….……………………………………………………………….…….…………………
……….. 
- Era addetto a depositi di polvere da sparo o depositi di munizioni?   |_| SI   |_| NO 
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Se si, ricorda con che materiale erano coibentate le pareti: 
...………………...…………………………….…….……………... 
………………………………………………………………………………………………………..…………………
….…….. 
- Se ha fatto il militare in marina specificare: 
 Era imbarcato?          |_| SI   |_| NO 
 Se si, su che tipo di unità navale? ……………………….……………………..... Anno di costruzione 
………..…………….. 
 Con quali mansioni? 
…………………………..………………………….…………….………………………………..……... 
 Ha svolto anche mansioni di manutenzione? 
 Se si , specificare quali: 
…………………………………………………………….………………………..…………………. 
 
NOTA: Se è stato prigioniero, chiedere se ha svolto attività lavorative particolari e descriverle sulla scheda per 
attività lavorative. 
_____________________________________________________________________________________________ 
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PARTE C: ESPOSIZIONE EXTRA-LAVORATIVA 
___________________________________________________________________________________________________________________________________________ 
 
C1. STORIA LAVORATIVA DEL FAMILIARI E CONVIVENTI 
(Riferita al periodo in cui hanno vissuto nella stessa casa del soggetto in esame) 
COMPOSIZIONE DELLA FAMIGLIA (solo i conviventi) 
 
Grado di Parentela 
Periodo di 
convivenza 
(dal… al…) 
Sommaria descrizione del lavoro 
(attività lavorativa svolta per più tempo) 
a 
* 
Abiti 
** 
Nome e attività dell’azienda Mansione   
Padre 
     
Madre      
Coniuge      
altro parente convivente      
*Il lavoro comportava l’utilizzo di amianto o manifatture contenenti amianto? **Gli indumenti di lavoro venivano portati a casa? 
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 In caso di risposta positiva, o di incertezza, nella colonna a compilare la seguente scheda: 
Congiunto: Grado di parentela …………………………………...……………………………………………...……….. 
 Cognome e Nome ……………………………..………………………… 
 Deceduto per …………………………………..………………………… 
 
(Elencare se possibile solo i lavori svolti durante il periodo di convivenza con il soggetto in esame) 
 Periodo Azienda Principali prodotti o 
servizi 
Attività del reparto Mansione e descrizione 
dell’attività svolta 
Abiti 
(a) 
Lavag. 
(b) 
 
 
      
 
 
      
 
 
      
 
 
      
 
 
      
 
 
      
 
 
      
(a) Barrare nel caso che rientrando dal lavoro portasse con sé gli indumenti di lavoro. 
(b) Barrare nel caso che gli indumenti di lavoro venissero spazzolati o lavati a casa. 
 
Il suo congiunto è in possesso di rendita INAIL per malattia professionale? 
|_| SI   |_| NO  |_| NON SO 
Se si, per quale malattia e da quando? ……………………………………………………………………...……………. 
…………………………………………………….………………………………………………...…….……………… 
…………………………………………………….………………………………………………...…….……………… 
…………………………………………………….………………………………………………...…….……………… 
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C2. STORIA RESIDENZIALE 
 
Periodo 
Dal … al … 
Comune Prov. Indirizzo Tipo di 
abitazione (*) 
     
     
     
     
     
     
     
     
     
 
(*) Tipi di abitazione: 1 = Rurale o Cascina  
 2 = Casa unifamiliare o Villa 
 3 = Condominio 
 4 = Comunità (pensionati, caserme, collegi, ricoveri) 
 5 = Altro (specificare) 
 
Nelle abitazioni successive al 1945 erano presenti manufatti in cemento amianto (coperture in eternit, 
controsoffittature, serbatoi d'acqua, altro)? ……………………………………………………………….……………… 
……………………………………….………………….………………………………………………………………... 
……………………………………………………………………………………………………………………………. 
……………………………………………………………………………………………………………………………. 
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Vicino alla sua abitazione, erano presenti (considerare tutte le abitazioni): 
|_| impianto chimico o petrolchimico   nel periodo ………….…… distanza………………….. 
|_| impianto siderurgico o fonderia   nel periodo ………….…… distanza………………….. 
|_| centrale termoelettrica    nel periodo ………….…… distanza………………….. 
|_| porto      nel periodo ………….…… distanza………………….. 
|_| cantiere navale     nel periodo ………….…… distanza………………….. 
|_| cementificio      nel periodo ………….…… distanza………………….. 
|_| impianto produzione eternit   nel periodo ………….…… distanza………………….. 
|_|  impianto produzione/riparazione rotabili ferroviari nel periodo ………….…… distanza………………….. 
|_| inceneritore o discarica    nel periodo ………….…… distanza………………….. 
|_| cava o miniera      nel periodo ………….…… distanza………………….. 
|_| altro      nel periodo ………….…… distanza………………….. 
 
 
C3. STORIA EXTRA-PROFESSIONALE 
______________________________________________________________________________________________ 
 
Faceva riparazioni in casa?  |_| SI   |_| NO  |_| NON SO Periodo ………….. 
Riparazioni di idraulica o di elettricità? |_| SI  |_| NO  |_| NON SO  Periodo ………….. 
Lavori di isolamento termico?   |_| SI  |_| NO  |_| NON SO  Periodo ………….. 
Lavori di muratura?   |_| SI  |_| NO  |_| NON SO  Periodo ………….. 
Altre riparazioni (specificare di che tipo e il periodo): …...…………………………..………………………………….. 
…………………………………………………………………………………...………….……………………………. 
……………………………………………………………………………………...……….……………………………. 
……………………………………………………………………………………...……….……………………………. 
 
Ha mai usato attrezzi domestici come: - guanti per forni  |_| Periodo ……………… 
     - pannelli di protezione dal fuoco  |_| Periodo ……………… 
     - asse da stiro con copertura in amianto |_| Periodo ……………… 
     - appoggiaferro da stiro   |_| Periodo ……………… 
 
Ha mai riparato la sua auto o altri mezzi meccanici (freni, frizione, tamburo, guarnizioni della testa)? 
|_| SI  |_| NO  |_| NON SO Periodo ……………………………………… 
 
Ha mai praticato attività nel suo tempo libero che comportassero l’uso di manufatti in amianto? 
   |_| SI  |_| NO  |_| NON SO 
Quali? ……...…………………………………………………………………… Periodo……..………………………. 
Quali? ……...…………………………………………………………………… Periodo……..………………………. 
Quali? ……...…………………………………………………………………… Periodo……..………………………. 
……………………………………………………………………………...………………………...………….……….. 
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Quanto assiduamente veniva svolta tale attività? 
 
|_| RARAMENTE |_| SPESSO (nel caso di secondo lavoro, 
inserirlo nella scheda di cui alla domanda B2) 
 
 
 
Ha fatto uso di talco cosmetico?       |_| SI   |_| NO 
 
Se si, specificare: 
Quando? ……………………………….…………………………………………………….. 
Quanto? ………………………………………………………….…………………………... 
 
Ha frequentato assiduamente locali di uso collettivo o mezzi di trasporto come: 
Periodo Durata Città 
 
Teatri …………………….. …………………. …………………… 
 
Cinema …………………….. …………………. …………………… 
 
Palestre …………………….. …………………. …………………… 
 
Piscine …………………….. …………………. …………………… 
 
Treno/metro/traghetto …………………….. …………………. …………………… 
 
Altro …………………….. …………………. …………………… 
 
 
______________________________________________________________________________________________ 
 ReNaM – Registro Nazionale Mesoteliomi – COR Lombardia 109 
PARTE D: SALUTE 
______________________________________________________________________________________________ 
D1. E’ stato sottoposto a radiodiagnostica una delle seguenti sedi? 
    SI NO NON SO  MOTIVO    N° 
 Testa    |_| |_| |_| ………………………….……………...…..…... .…..... 
 Torace    |_| |_| |_| ………………………….……………...…..…... .…..... 
 Addome    |_| |_| |_| ………………………….……………...…..…... .…..... 
 Rene, vescica, ureteri  |_| |_| |_| ………………………….……………...…..…... .…..... 
 Colonna vertebrale   |_| |_| |_| ………………………….……………...…..…... .…..... 
 Altre sedi (specificare)  |_| |_| |_| ………………………….……………...…..…... .…..... 
 ………………………………………………………... ………………………….……………...…..…... .…..... 
 
D2. E’ mai stato sottoposto a trattamenti terapeutici con raggi X?  |_| SI  |_| NO  |_| NON SO 
Sede   Motivo   Durata (mesi)   Ospedale   Anno di inizio 
……….….….………………..…........ ..….…….………….… ……………………..… ……..…..…………......... 
……….….….……………..……........ …………...……..…… ……….……..……..… ………...……..……......... 
……………….….….….…..……....... …………...…….……. …….………..……..… …….……..…..……......... 
 
D3. E’/è stato in possesso di rendita INAIL per malattia professionale dell’albero respiratorio? 
      |_| SI  |_| NO  |_| NON SO 
Se si, per quale malattia e da quando? …………………………………………………………………………………… 
……………………………………………………………………………...……………..……………………………… 
D4. Ha mai sofferto di TBC pleuro/polmonare?  |_| SI  |_| NO  |_| NON SO 
D5. Ha mai subito importanti traumi toracici?  |_| SI  |_| NO  |_| NON SO 
D6. Nella sua famiglia ci sono stati casi di patologia tumorale? |_| SI  |_| NO |_| NON SO 
Se si, specificare: 
Grado parentela     Tumore     Anno di inizio 
……….….….………………..… …………...….…….………….… ……………………..… ……..…..………… 
……….….….……………..…… …………...……..…….………… ……….……..……..… ………...……..…… 
……….….….……………..…… …………...……..…….………… ……….……..……..… ………...……..…… 
______________________________________________________________________________________________ 
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ATTENDIBILITÀ DELLE RISPOSTE 
______________________________________________________________________________________________ 
 
1. Completezza delle informazioni 
    Scarsa    Parziale     Sufficiente 
2. Atteggiamento nei confronti dell'intervista 
    Favorevole   Con qualche riserva   Negativo 
3. Motivazione a collaborare 
    Buona    Discreta     Bassa 
4. Stato di salute del paziente 
    Buono    Compromesso    Intervista non applicabile 
  (intervista a sostituto) 
5. Il paziente è a conoscenza della patologia 
    Completamente  Parzialmente    Non è a conoscenza 
6. I famigliari sono a conoscenza della patologia del paziente 
    Completamente  Parzialmente    Non sono a conoscenza 
 
Esistono altri parenti o compagni di lavoro del soggetto che potrebbero dare risposte più approfondite rispetto ad 
alcuni particolari periodi? Se si, riportare se possibile indirizzo e numero di telefono. 
…………………………………………...……………………………………………………...………………….…….. 
…………………………………………...……………………………………………………...………………….…….. 
…………………………………………………………………………………..………………………………………... 
……………………………………………………………………………………………………………………...…….. 
 
NOTE: ……………………………………………………………………………………………………………………. 
…………………………………………………………………………………..………………………………………... 
…………………………………………………………………………………..………………………………………... 
 
Data |__|__| / |__|__| / |__|__|__|__| 
 
Luogo dell’intervista       Firma dell'intervistatore 
……..……………..……………………..……………. ……...……………...………………………... 
Sono stati redatti Primo certificato e Denuncia/Referto di Malattia Professionale? |_| SI  |_| NO 
Dal Dr./Dr.ssa............................................................................................  In data |_|_| / |_|_| / |_|_|_|_| 
______________________________________________________________________________________________ 
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APPENDIX B –EBC DIFFERENTIAL MIRNAS 
MPM vs PEA 
 
MPM vs NM 
miRBase ID(s) FC p-values 
 
miRBase ID(s) FC p-values 
hsa-miR-30a-5p 0.280753 0.005943 
 
hsa-miR378 0.049168 0.014848 
hsa-miR-520d-3p 0.008541 0.006966 
 
hsa-miR206 0.110251 0.031217 
hsa-miR-518b 0.021609 0.013594 
 
hsa-miR9 0.265293 0.043812 
hsa-miR-520b 3.831813 0.014748 
    hsa-miR-646 10.99091 0.020164 
    hsa-miR-520c-3p 13.18051 0.02331 
    hsa-miR-888-5p 11.02651 0.039851 
    hsa-miR-376a-3p 2.117156 0.04988 
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APPENDIX B – PLASMA DIFFERENTIAL MIRNAS 
MPM vs PEA 
 
MPM vs NM 
miRBase ID(s) FC p-values 
 
miRBase ID(s) FC p-values 
hsa-miR-628-3p 0.37568 0.000218 
 
hsa-miR-489-3p 0.155677 0.000188 
hsa-miR-151a-5p 0.286561 0.000295 
 
hsa-miR-375 0.164129 0.001423 
hsa-miR-93-3p 0.300425 0.000321 
 
hsa-miR-483-3p 0.246724 0.001587 
hsa-miR-98-5p 0.049642 0.000341 
 
hsa-miR-190a-5p 0.307291 0.003612 
hsa-miR-30d-5p 0.328762 0.000617 
 
hsa-miR-642a-5p 0.239922 0.00498 
hsa-miR-148b-5p 0.286644 0.000628 
 
hsa-miR-25-3p 0.35171 0.007322 
hsa-miR-589-3p 0.179872 0.00081 
 
hsa-miR-378 0.106803 0.007725 
hsa-miR-340-3p 0.284145 0.000907 
 
hsa-miR-365a-3p 0.217752 0.009835 
hsa-miR-130b-5p 0.284536 0.001071 
 
hsa-miR-144-5p 0.303538 0.011222 
hsa-miR-505-5p 0.34804 0.00113 
 
hsa-let-7c-5p 0.313274 0.011242 
hsa-miR-103a-3p 0.271125 0.001192 
 
hsa-miR-193a-5p 0.294463 0.012173 
hsa-miR-625-3p 5.184904 0.001387 
 
hsa-miR-886-3p 0.266727 0.013006 
hsa-miR-766-3p 0.297441 0.001499 
 
hsa-miR-200a-3p 0.244418 0.013385 
hsa-miR-942-5p 6.791041 0.001671 
 
hsa-miR-450b-3p 0.194443 0.014373 
hsa-miR-409-3p 0.268254 0.001673 
 
hsa-miR-218-5p 0.328296 0.014559 
hsa-miR-126-5p 0.327779 0.001687 
 
hsa-miR-455-3p 0.36225 0.016966 
hsa-miR-30a-5p 0.287003 0.001689 
 
hsa-miR-31-5p 0.165954 0.017124 
hsa-miR-146b-3p 0.421028 0.001756 
 
hsa-miR-885-5p 0.238934 0.017673 
hsa-miR-1260a 7.259183 0.00225 
 
hsa-miR-122-5p 0.245242 0.017978 
hsa-miR-20a-3p 0.309987 0.002301 
 
hsa-miR-320b 0.371009 0.018165 
hsa-miR-151a-3p 0.31479 0.002386 
 
hsa-miR-193b-5p 0.402687 0.022523 
hsa-miR-127-3p 0.271098 0.002422 
 
hsa-miR-135b-5p 0.409626 0.022817 
hsa-miR-183-5p 1.921576 0.003084 
 
hsa-miR-125b-1-3p 0.139646 0.024671 
hsa-miR-223-5p 0.425485 0.003181 
 
hsa-miR-99a-5p 0.34446 0.027242 
hsa-miR-181a-2-3p 0.358715 0.003329 
 
hsa-miR-1255b-5p 0.507204 0.02998 
hsa-miR-23a-3p 0.329772 0.003419 
 
hsa-miR-500a-5p 0.392921 0.030402 
hsa-miR-654-5p 2.305953 0.0035 
 
hsa-miR-654-5p 0.328002 0.033774 
hsa-miR-154-3p 0.319475 0.003509 
 
hsa-miR-193b-3p 0.292076 0.034166 
hsa-miR-543 0.329703 0.003581 
 
hsa-miR-455-5p 0.460077 0.035092 
hsa-miR-26b-3p 0.455529 0.004025 
 
hsa-miR-125b-5p 0.315456 0.035174 
hsa-miR-383-5p 2.25916 0.004616 
 
hsa-miR-1275 0.315488 0.035651 
hsa-miR-30e-3p 0.255835 0.004796 
 
hsa-miR-101-3p 0.394766 0.038064 
hsa-miR-646 11.45214 0.004834 
 
hsa-miR-92a-3p 0.371828 0.040274 
hsa-miR-147a 1.810541 0.005134 
 
hsa-miR-16-5p 0.427593 0.040558 
hsa-miR-23b-3p 0.060484 0.005269 
 
hsa-miR-660-5p 0.351997 0.040896 
hsa-miR-494-3p 0.290693 0.00604 
 
hsa-miR-202-3p 0.50283 0.040991 
hsa-miR-142-3p 0.427734 0.006093 
 
hsa-miR-34b-3p 0.530273 0.043945 
hsa-miR-106b-3p 0.134365 0.006446 
 
hsa-miR-27a-5p 0.419498 0.048065 
hsa-miR-335-3p 0.168747 0.006659 
 
hsa-miR-216b-5p 0.467026 0.048246 
hsa-miR-510-5p 1.879752 0.006786 
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MPM vs PEA     
miRBase ID(s) FC p-values     
hsa-miR-618 1.775793 0.006933     
hsa-miR-504-5p 1.775793 0.006933 
    hsa-miR-450b-3p 1.775793 0.006933 
    hsa-miR-455-3p 1.775793 0.006933 
    hsa-let-7e-5p 0.446778 0.007211 
    hsa-miR-29a-5p 0.380887 0.007232 
    hsa-miR-19b-1-5p 0.444879 0.007279 
    hsa-miR-1249 0.422312 0.007541 
    hsa-miR-324-5p 0.330102 0.007572 
    hsa-miR-145-5p 0.318175 0.007834 
    hsa-miR-671-3p 0.416829 0.007884 
    hsa-miR-590-3p 0.382217 0.009052 
    hsa-miR-29b-3p 0.398221 0.010212 
    hsa-miR-181a-3p 0.327098 0.010286 
    hsa-miR-30d-3p 0.416286 0.010381 
    hsa-miR-22-5p 0.494648 0.011048 
    hsa-miR-382-5p 0.054696 0.011306 
    hsa-miR-18a-5p 0.474983 0.011415 
    hsa-miR-361-5p 0.405237 0.011898 
    hsa-miR-221-3p 0.450861 0.011941 
    hsa-miR-181c-5p 0.345878 0.012318 
    hsa-miR-519a-3p 1.717979 0.013458 
    hsa-miR-302c-5p 8.984328 0.013772 
    hsa-miR-744-3p 0.421244 0.013926 
    hsa-let-7c-5p 0.417543 0.01407 
    hsa-miR-191-3p 0.504484 0.014885 
    hsa-miR-27a-3p 0.459145 0.015183 
    hsa-let-7f-5p 0.485009 0.015216 
    hsa-miR-375 0.356058 0.015341 
    hsa-miR-744-5p 0.412421 0.015574 
    hsa-miR-589-5p 1.685922 0.015658 
    hsa-miR-450b-5p 1.637586 0.015666 
    hsa-miR-199a-5p 0.427968 0.016023 
    hsa-miR-508-3p 1.918199 0.016167 
    hsa-miR-548b-3p 1.708638 0.016865 
    hsa-miR-136-3p 0.338666 0.017635 
    hsa-miR-136-5p 1.663488 0.017848 
    hsa-let-7a-5p 0.199848 0.01785 
    hsa-miR-125a-5p 0.372199 0.018199 
    hsa-miR-130b-3p 0.395922 0.018232 
    hsa-miR-526b-5p 1.670495 0.018637 
    hsa-miR-432-5p 0.376884 0.019793 
    hsa-miR-142-5p 0.442703 0.020104 
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MPM vs PEA 
    miRBase ID(s) FC p-values 
    hsa-miR-15b-5p 0.350969 0.020833     
hsa-miR-320b 0.50541 0.020848     
hsa-let-7d-5p 0.386217 0.021384 
    hsa-miR-485-3p 0.304979 0.021825 
    hsa-miR-30a-3p 0.432392 0.02269 
    hsa-miR-101-3p 0.503494 0.022767 
    hsa-miR-128-3p 0.511282 0.023593 
    hsa-miR-127-5p 1.578706 0.025101 
    hsa-miR-125a-3p 1.69695 0.026312 
    hsa-miR-135a-5p 0.483027 0.026349 
    hsa-miR-29c-3p 0.512421 0.027172 
    hsa-miR-30b-5p 0.292208 0.028398 
    hsa-miR-326 0.53148 0.028812 
    hsa-miR-15a-3p 0.490211 0.029044 
    hsa-miR-301b 0.475846 0.029758 
    hsa-miR-15a-5p 0.091591 0.030228 
    hsa-miR-579-3p 0.4953 0.030328 
    hsa-miR-373-3p 1.685615 0.030388 
    hsa-miR-503-5p 0.520033 0.030929 
    hsa-miR-652-3p 0.436477 0.031566 
    hsa-miR-181a-5p 0.359646 0.032169 
    hsa-miR-27b-3p 0.503086 0.032922 
    hsa-miR-148b-3p 0.479335 0.03421 
    hsa-miR-107 0.422768 0.034922 
    hsa-miR-199b-5p 0.449518 0.035547 
    hsa-miR-629-3p 0.556286 0.035786 
    hsa-miR-758-3p 7.214694 0.036851 
    hsa-miR-222-3p 0.467657 0.039743 
    hsa-miR-328-3p 0.538681 0.041034 
    hsa-miR-339-5p 0.204598 0.041149 
    rno-miR-301a-3p 0.481937 0.041396 
    hsa-miR-99b-5p 0.498538 0.041484 
    hsa-miR-374a-5p 0.568027 0.044481 
    hsa-miR-520e 20.6435 0.046595 
    hsa-miR-324-3p 0.533766 0.046734 
    hsa-miR-551b-3p 0.413438 0.048161 
    hsa-miR-32-5p 0.499282 0.048162 
    hsa-miR-331-3p 0.545767 0.048407 
    hsa-miR-376b-3p 0.504434 0.048735 
    hsa-miR-208a-3p 1.56183 0.048768 
    hsa-miR-146a-5p 0.369494 0.049217 
       
     
